lenalidomide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3317 191732-72-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lenalidomide hydrate
  • lenalidomide
  • revimid
  • revlimid
Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q) myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-alpha and IL-6) by monocytes. In multiple myeloma cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
  • Molecular weight: 259.27
  • Formula: C13H13N3O3
  • CLOGP: -0.41
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 92.50
  • ALOGS: -2.05
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 66 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.38 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
June 14, 2007 EMA CELEGENE EUROPE BV
Dec. 27, 2005 FDA CELGENE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plasma cell myeloma 12211.04 14.30 5425 226861 39053 46414723
Full blood count decreased 5121.66 14.30 2404 229882 19807 46433969
Death 4091.65 14.30 6526 225760 329022 46124754
Diarrhoea 3085.05 14.30 7810 224476 551792 45901984
White blood cell count decreased 2844.87 14.30 3134 229152 109097 46344679
Thrombosis 2605.33 14.30 2188 230098 53881 46399895
Neuropathy peripheral 2491.07 14.30 2646 229640 88247 46365529
Pneumonia 2265.53 14.30 5443 226843 370877 46082899
Laboratory test abnormal 2100.13 14.30 1347 230939 21500 46432276
Platelet count decreased 2020.56 14.30 2487 229799 97537 46356239
Adverse drug reaction 1415.53 14.30 1403 230883 42959 46410817
Unevaluable event 1341.17 14.30 1388 230898 44787 46408989
Fatigue 1062.84 14.30 5873 226413 602824 45850952
Drug ineffective 1046.90 14.30 1104 231182 676734 45777042
Rheumatoid arthritis 1039.52 14.30 35 232251 240180 46213596
Off label use 1017.68 14.30 314 231972 379527 46074249
Rash 978.66 14.30 3928 228358 352584 46101192
Human chorionic gonadotropin increased 925.62 14.30 313 231973 914 46452862
Plasma cell myeloma recurrent 783.18 14.30 332 231954 2075 46451701
Condition aggravated 761.63 14.30 148 232138 244904 46208872
Neutropenia 745.33 14.30 1966 230320 141238 46312538
Constipation 739.49 14.30 2220 230066 171877 46281899
Muscle spasms 731.08 14.30 1777 230509 121336 46332440
Myelodysplastic syndrome 720.01 14.30 609 231677 15102 46438674
Drug interaction 719.41 14.30 84 232202 203010 46250766
Completed suicide 683.07 14.30 8 232278 145912 46307864
Deep vein thrombosis 679.49 14.30 1332 230954 78441 46375335
Pancytopenia 643.39 14.30 1352 230934 83706 46370070
Haemoglobin decreased 602.52 14.30 1702 230584 127247 46326529
Blood potassium decreased 594.14 14.30 835 231451 37228 46416548
Product dose omission issue 574.80 14.30 1994 230292 166526 46287250
Neutrophil count decreased 567.22 14.30 876 231410 42550 46411226
Drug hypersensitivity 487.45 14.30 306 231980 243519 46210257
Maternal exposure during pregnancy 487.39 14.30 4 232282 102545 46351231
Ageusia 481.61 14.30 423 231863 11049 46442727
Exposure during pregnancy 463.25 14.30 17 232269 108195 46345581
Injection site pain 461.61 14.30 16 232270 107136 46346640
Red blood cell count decreased 449.87 14.30 675 231611 31948 46421828
Renal disorder 447.30 14.30 606 231680 26080 46427696
Tooth disorder 446.18 14.30 565 231721 22738 46431038
Skin discolouration 444.71 14.30 672 231614 32008 46421768
Headache 424.58 14.30 1113 231173 477239 45976537
Plasmacytoma 400.71 14.30 211 232075 2266 46451510
Thrombocytopenia 395.47 14.30 1456 230830 125125 46328651
Multiple allergies 394.95 14.30 313 231973 7058 46446718
Cytopenia 382.60 14.30 314 231972 7454 46446322
COVID-19 382.26 14.30 467 231819 18108 46435668
Pulmonary thrombosis 381.00 14.30 307 231979 7095 46446681
Asthenia 358.11 14.30 2709 229577 308366 46145410
Overdose 353.84 14.30 45 232241 101934 46351842
Arthralgia 340.35 14.30 826 231460 363777 46089999
Peripheral swelling 334.27 14.30 1614 230672 156457 46297319
Seasonal allergy 334.17 14.30 371 231915 12963 46440813
Cardiac disorder 327.66 14.30 694 231592 43164 46410612
Dehydration 299.29 14.30 1575 230711 157965 46295811
Hip fracture 297.84 14.30 500 231786 26056 46427720
Rash pruritic 296.60 14.30 670 231616 43545 46410231
Product use issue 281.53 14.30 63 232223 94581 46359195
Taste disorder 279.88 14.30 233 232053 5645 46448131
Synovitis 278.54 14.30 5 232281 61070 46392706
Acute myeloid leukaemia 277.68 14.30 367 231919 15411 46438365
Blood test abnormal 275.74 14.30 286 232000 9234 46444542
Therapeutic product effect incomplete 272.27 14.30 34 232252 78119 46375657
Injection site erythema 270.26 14.30 28 232258 74399 46379377
Full blood count increased 268.53 14.30 117 232169 789 46452987
Psoriasis 262.45 14.30 39 232247 78565 46375211
Systemic lupus erythematosus 260.36 14.30 16 232270 65164 46388612
Cataract 258.92 14.30 646 231640 44769 46409007
Plasma cell leukaemia 249.76 14.30 121 232165 1072 46452704
Pain 246.56 14.30 1381 230905 475567 45978209
Blood count abnormal 246.52 14.30 370 231916 17508 46436268
Monoclonal immunoglobulin present 239.18 14.30 102 232184 648 46453128
Suicide attempt 237.72 14.30 8 232278 55028 46398748
Dry skin 237.58 14.30 587 231699 40429 46413347
Renal failure 233.56 14.30 1151 231135 112443 46341333
Product use in unapproved indication 231.42 14.30 80 232206 90193 46363583
Hospitalisation 229.74 14.30 24 232262 63361 46390415
Adult T-cell lymphoma/leukaemia 225.91 14.30 79 232207 263 46453513
Anaemia 224.39 14.30 2097 230189 253682 46200094
Protein total increased 223.96 14.30 145 232141 2348 46451428
Infusion related reaction 223.53 14.30 112 232174 101096 46352680
Spinal fracture 222.90 14.30 325 231961 14980 46438796
Treatment failure 219.54 14.30 94 232192 92993 46360783
Alanine aminotransferase increased 217.24 14.30 84 232202 88367 46365409
Body height decreased 208.91 14.30 249 232037 9403 46444373
Aspartate aminotransferase increased 208.29 14.30 66 232220 78634 46375142
Wrong technique in product usage process 206.86 14.30 17 232269 54405 46399371
Intentional product misuse 206.60 14.30 6 232280 47122 46406654
Abortion spontaneous 201.41 14.30 3 232283 43643 46410133
Intentional product use issue 199.20 14.30 17 232269 52763 46401013
Tachycardia 198.77 14.30 125 232161 99497 46354279
Light chain analysis increased 195.02 14.30 99 232187 979 46452797
Influenza 188.77 14.30 912 231374 88358 46365418
Suicidal ideation 188.14 14.30 28 232258 56354 46397422
Injection site reaction 184.51 14.30 14 232272 47835 46405941
Hyponatraemia 183.80 14.30 141 232145 101191 46352585
Depression 180.84 14.30 358 231928 169746 46284030
Gastric disorder 179.41 14.30 405 231881 26300 46427476
Urinary tract infection 178.31 14.30 1776 230510 218490 46235286
Anaphylactic reaction 178.09 14.30 26 232260 53086 46400690
Oxygen saturation decreased 177.76 14.30 61 232225 69103 46384673
Pulmonary embolism 172.17 14.30 1025 231261 107560 46346216
Myelodysplastic syndrome transformation 171.59 14.30 70 232216 391 46453385
Injection site pruritus 170.85 14.30 6 232280 39737 46414039
Hypertension 167.31 14.30 465 231821 195891 46257885
Sepsis 166.99 14.30 1204 231082 134810 46318966
Pruritus 164.88 14.30 1887 230399 240465 46213311
Therapeutic product effect decreased 158.85 14.30 108 232178 82493 46371283
Migraine 158.38 14.30 75 232211 69951 46383825
Injection site bruising 158.21 14.30 4 232282 35632 46418144
Fall 157.09 14.30 2402 229884 326695 46127081
Diffuse large B-cell lymphoma 155.32 14.30 169 232117 5769 46448007
Injection site swelling 154.92 14.30 12 232274 40315 46413461
Coma 154.26 14.30 49 232237 58300 46395476
Inappropriate schedule of product administration 144.94 14.30 71 232215 64942 46388834
Product quality issue 144.64 14.30 8 232278 35640 46418136
Depressed level of consciousness 142.76 14.30 31 232255 47538 46406238
Abdominal pain 142.59 14.30 624 231662 229407 46224369
Back disorder 140.26 14.30 199 232087 8942 46444834
Mobility decreased 136.87 14.30 65 232221 60529 46393247
Hypoglycaemia 136.12 14.30 50 232236 54299 46399477
Rhabdomyolysis 134.89 14.30 23 232263 41886 46411890
Lactose intolerance 134.88 14.30 105 232181 2304 46451472
SARS-CoV-2 test positive 132.56 14.30 95 232191 1830 46451946
Bradycardia 132.47 14.30 83 232203 66215 46387561
Sinus disorder 131.72 14.30 269 232017 16294 46437482
Amyloidosis 131.36 14.30 77 232209 1034 46452742
Squamous cell carcinoma of skin 128.59 14.30 143 232143 5004 46448772
Agitation 124.32 14.30 60 232226 55355 46398421
Anxiety 121.79 14.30 479 231807 181478 46272298
Drug withdrawal syndrome 118.17 14.30 4 232282 27380 46426396
Somnolence 115.27 14.30 396 231890 156125 46297651
Lactic acidosis 115.07 14.30 16 232270 33893 46419883
Pulmonary arterial hypertension 114.76 14.30 3 232283 25925 46427851
Tumour flare 113.64 14.30 46 232240 251 46453525
Atrial fibrillation 112.98 14.30 892 231394 102698 46351078
Blood pressure increased 112.30 14.30 294 231992 126372 46327404
Skin exfoliation 112.12 14.30 390 231896 32548 46421228
Interstitial lung disease 111.33 14.30 65 232221 53884 46399892
Upper limb fracture 109.68 14.30 242 232044 15471 46438305
Blood creatine phosphokinase increased 107.20 14.30 8 232278 27716 46426060
Electrocardiogram QT prolonged 107.11 14.30 61 232225 51264 46402512
Loss of personal independence in daily activities 106.97 14.30 77 232209 57106 46396670
Fibromyalgia 106.93 14.30 25 232261 36438 46417338
Blood pressure systolic increased 106.65 14.30 10 232276 28777 46424999
Vomiting 106.62 14.30 1599 230687 451195 46002581
Drug intolerance 106.20 14.30 1159 231127 145890 46307886
Decreased appetite 105.81 14.30 1449 230837 192387 46261389
Clostridium difficile infection 104.16 14.30 318 231968 24785 46428991
Immune system disorder 103.90 14.30 161 232125 7834 46445942
Dysgeusia 102.96 14.30 437 231849 40054 46413722
Hordeolum 102.20 14.30 86 232200 2115 46451661
Hypoaesthesia 101.65 14.30 970 231316 117899 46335877
Gamma-glutamyltransferase increased 100.87 14.30 18 232268 31722 46422054
Emotional distress 100.72 14.30 16 232270 30691 46423085
Osteoarthritis 100.60 14.30 96 232190 61929 46391847
Mantle cell lymphoma 100.32 14.30 52 232234 539 46453237
Seizure 97.03 14.30 302 231984 122752 46331024
C-reactive protein increased 97.01 14.30 89 232197 58501 46395275
Knee arthroplasty 96.98 14.30 5 232281 23660 46430116
Disease progression 95.63 14.30 779 231507 90521 46363255
Respiratory arrest 95.63 14.30 25 232261 33791 46419985
Medication error 95.10 14.30 19 232267 30892 46422884
Dementia 94.28 14.30 221 232065 14709 46439067
Injury 93.78 14.30 51 232235 43976 46409800
Chest discomfort 93.26 14.30 193 232093 90076 46363700
Palpitations 93.17 14.30 210 232076 95049 46358727
Erythema 92.98 14.30 380 231906 142440 46311336
Surgery 92.19 14.30 16 232270 28769 46425007
Hyperkalaemia 91.35 14.30 71 232215 50638 46403138
Cardio-respiratory arrest 89.91 14.30 99 232187 59770 46394006
Incorrect dose administered 89.65 14.30 58 232228 45492 46408284
Multiple sclerosis 88.25 14.30 10 232276 24781 46428995
Bone lesion 87.21 14.30 115 232171 4816 46448960
Wheezing 86.15 14.30 83 232203 53303 46400473
Injection site haemorrhage 86.06 14.30 4 232282 20705 46433071
Nasopharyngitis 83.90 14.30 1151 231135 152847 46300929
Cardiac amyloidosis 83.75 14.30 44 232242 470 46453306
Ascites 82.99 14.30 39 232247 36545 46417231
Blood alkaline phosphatase increased 82.75 14.30 47 232239 39562 46414214
Cerebrovascular accident 82.67 14.30 817 231469 100222 46353554
Sedation 82.16 14.30 9 232277 22901 46430875
Gout 81.65 14.30 177 232109 11179 46442597
Flatulence 81.59 14.30 322 231964 28556 46425220
Glossodynia 81.37 14.30 61 232225 44312 46409464
Device dislocation 79.64 14.30 8 232278 21794 46431982
Gallbladder disorder 79.57 14.30 229 232057 17269 46436507
Papule 78.81 14.30 102 232184 4193 46449583
5q minus syndrome 78.78 14.30 31 232255 155 46453621
Infection 78.36 14.30 1012 231274 132580 46321196
Underdose 77.49 14.30 5 232281 19553 46434223
Dysarthria 76.21 14.30 46 232240 37452 46416324
No adverse event 75.35 14.30 38 232248 34193 46419583
Bone pain 75.11 14.30 444 231842 46446 46407330
Hepatic enzyme increased 74.64 14.30 187 232099 81600 46372176
Toxic epidermal necrolysis 74.45 14.30 11 232275 22267 46431509
Myalgia 74.28 14.30 337 231949 122751 46331025
Device issue 73.86 14.30 7 232279 19973 46433803
Acute lymphocytic leukaemia 72.66 14.30 79 232207 2694 46451082
Pregnancy test false positive 72.44 14.30 29 232257 153 46453623
Pregnancy 71.34 14.30 23 232263 27114 46426662
Blood magnesium decreased 70.82 14.30 164 232122 10828 46442948
Bronchitis 70.43 14.30 822 231464 105157 46348619
Metabolic acidosis 70.23 14.30 54 232232 38726 46415050
Renal impairment 70.16 14.30 620 231666 73752 46380024
Generalised tonic-clonic seizure 69.53 14.30 24 232262 27098 46426678
Discomfort 69.17 14.30 78 232208 46592 46407184
Dyspnoea 69.10 14.30 1996 230290 513552 45940224
Abnormal behaviour 69 14.30 11 232275 21047 46432729
Incorrect route of product administration 68.62 14.30 3 232283 16380 46437396
Gait disturbance 68.61 14.30 432 231854 144831 46308945
Metastases to liver 67.02 14.30 9 232277 19576 46434200
Blood pressure fluctuation 66.72 14.30 34 232252 30414 46423362
Monoclonal immunoglobulin increased 66.59 14.30 23 232263 73 46453703
Flushing 66.01 14.30 139 232147 64475 46389301
Anaphylactic shock 65.52 14.30 11 232275 20263 46433513
Withdrawal syndrome 65.35 14.30 7 232279 18127 46435649
Unresponsive to stimuli 64.64 14.30 40 232246 32134 46421642
Hypogeusia 64.14 14.30 48 232238 991 46452785
Cardiac arrest 63.63 14.30 233 232053 90166 46363610
Hip arthroplasty 62.76 14.30 8 232278 18104 46435672
Drug ineffective for unapproved indication 62.71 14.30 5 232281 16408 46437368
Heart rate increased 62.20 14.30 179 232107 74612 46379164
Diverticulitis 61.65 14.30 326 231960 32713 46421063
Musculoskeletal stiffness 61.10 14.30 265 232021 97728 46356048
Dyskinesia 60.88 14.30 34 232252 28891 46424885
Diabetic ketoacidosis 60.84 14.30 9 232277 18201 46435575
Hepatitis 60.74 14.30 43 232243 32172 46421604
Sleep apnoea syndrome 59.82 14.30 18 232268 22183 46431593
Liver function test abnormal 59.27 14.30 87 232199 46400 46407376
Intraductal proliferative breast lesion 58.98 14.30 69 232217 2553 46451223
Hepatic steatosis 58.72 14.30 23 232263 24019 46429757
Right ventricular failure 58.54 14.30 6 232280 16087 46437689
Lymphoma 58.44 14.30 142 232144 9671 46444105
Product prescribing error 58.27 14.30 14 232272 20033 46433743
Obesity 58.21 14.30 3 232283 14203 46439573
Acute leukaemia 58.13 14.30 47 232239 1091 46452685
Hyperviscosity syndrome 56.83 14.30 25 232261 173 46453603
Inflammation 56.79 14.30 97 232189 48684 46405092
Joint range of motion decreased 56.70 14.30 5 232281 15119 46438657
Spinal compression fracture 55.92 14.30 166 232120 12737 46441039
Osteolysis 55.89 14.30 67 232219 2545 46451231
Encephalopathy 55.62 14.30 51 232235 33538 46420238
Type 2 diabetes mellitus 55.61 14.30 15 232271 19860 46433916
Pallor 55.21 14.30 23 232263 23143 46430633
Transaminases increased 55.10 14.30 35 232251 27726 46426050
Herpes zoster 55.09 14.30 548 231738 67324 46386452
Hallucination, visual 54.95 14.30 11 232275 17862 46435914
Musculoskeletal pain 54.62 14.30 173 232113 69955 46383821
Tumour lysis syndrome 54.57 14.30 115 232171 7121 46446655
Eye disorder 54.28 14.30 206 232080 17935 46435841
Fear 54.01 14.30 8 232278 16164 46437612
Aggression 53.53 14.30 23 232263 22721 46431055
Depressed mood 53.52 14.30 52 232234 33267 46420509
Eye swelling 53.47 14.30 220 232066 19883 46433893
Metastases to bone 53.22 14.30 11 232275 17465 46436311
Drug-induced liver injury 53.13 14.30 30 232256 25338 46428438
Cyanosis 53.11 14.30 8 232278 15963 46437813
Agranulocytosis 52.91 14.30 22 232264 22163 46431613
Compression fracture 52.58 14.30 104 232182 6153 46447623
Hepatocellular injury 52.33 14.30 42 232244 29480 46424296
Vitamin D decreased 52.21 14.30 119 232167 7774 46446002
International normalised ratio increased 52.08 14.30 96 232190 46787 46406989
Crying 52.00 14.30 20 232266 21121 46432655
Blood bilirubin increased 51.90 14.30 56 232230 34128 46419648
Memory impairment 51.88 14.30 601 231685 76736 46377040
Accidental exposure to product 51.76 14.30 20 232266 21061 46432715
Pancreatitis acute 51.26 14.30 30 232256 24842 46428934
Blood iron decreased 51.20 14.30 146 232140 10951 46442825
Impaired work ability 50.75 14.30 3 232283 12633 46441143
Swelling face 50.38 14.30 443 231843 52616 46401160
Lower respiratory tract infection 50.22 14.30 126 232160 54963 46398813
Blood pressure diastolic decreased 49.92 14.30 6 232280 14205 46439571
Pathological fracture 49.45 14.30 117 232169 7833 46445943
Therapeutic response unexpected 49.31 14.30 9 232277 15607 46438169
Hypoacusis 49.24 14.30 221 232065 20748 46433028
Feeling jittery 49.02 14.30 143 232143 10865 46442911
Liver injury 48.88 14.30 10 232276 15991 46437785
Status epilepticus 48.86 14.30 6 232280 13973 46439803
Angioedema 48.83 14.30 75 232211 39267 46414509
Device malfunction 48.61 14.30 5 232281 13369 46440407
Epilepsy 48.40 14.30 29 232257 23709 46430067
Coronary artery disease 48.30 14.30 58 232228 33694 46420082
Blood cholesterol increased 48.03 14.30 78 232208 39935 46413841
B-cell lymphoma 48.03 14.30 70 232216 3224 46450552
Procedural pain 47.71 14.30 5 232281 13174 46440602
Stress 47.70 14.30 117 232169 51434 46402342
White blood cell count abnormal 47.67 14.30 89 232197 5043 46448733
Coronavirus infection 47.63 14.30 64 232222 2730 46451046
Dyspnoea exertional 47.43 14.30 113 232173 50176 46403600
Gastrointestinal disorder 47.38 14.30 479 231807 59097 46394679
Cardiac failure congestive 47.19 14.30 679 231607 91071 46362705
Increased tendency to bruise 47.02 14.30 128 232158 9346 46444430
Clostridium difficile colitis 46.97 14.30 200 232086 18353 46435423
Hyperlipidaemia 46.50 14.30 17 232269 18522 46435254
Sinus tachycardia 46.21 14.30 25 232261 21624 46432152
Adenocarcinoma of colon 45.96 14.30 55 232231 2085 46451691
Acute kidney injury 45.79 14.30 862 231424 234993 46218783
Leukocytosis 45.75 14.30 30 232256 23368 46430408
Full blood count abnormal 45.74 14.30 47 232239 1500 46452276
Hypercholesterolaemia 45.52 14.30 3 232283 11527 46442249
Delirium 45.22 14.30 72 232214 37156 46416620
Muscle spasticity 45.10 14.30 3 232283 11437 46442339
Lower limb fracture 44.99 14.30 150 232136 12248 46441528
Coagulopathy 44.68 14.30 18 232268 18481 46435295
Fracture 44.39 14.30 181 232105 16290 46437486
Extrapyramidal disorder 44.29 14.30 3 232283 11265 46442511
Light chain analysis abnormal 44.12 14.30 19 232267 124 46453652
Haematemesis 43.94 14.30 47 232239 28759 46425017
Hepatotoxicity 43.80 14.30 36 232250 24973 46428803
Myoclonus 43.78 14.30 9 232277 14343 46439433
Oedema peripheral 43.76 14.30 1072 231214 158634 46295142
Pneumonia aspiration 43.45 14.30 56 232230 31549 46422227
Neutrophil count increased 43.35 14.30 9 232277 14244 46439532
Human chorionic gonadotropin abnormal 43.24 14.30 13 232273 22 46453754
Blood electrolytes decreased 43.23 14.30 38 232248 993 46452783
Hypothermia 43.15 14.30 5 232281 12178 46441598
General physical health deterioration 42.78 14.30 369 231917 115400 46338376
COVID-19 pneumonia 42.62 14.30 66 232220 3209 46450567
Blood potassium abnormal 42.46 14.30 52 232234 2020 46451756
Pulmonary hypertension 42.42 14.30 71 232215 35922 46417854
Transformation to acute myeloid leukaemia 42.38 14.30 18 232268 113 46453663
Weight decreased 42.31 14.30 1360 230926 209489 46244287
Injection site rash 42.28 14.30 13 232273 15800 46437976
Colitis ulcerative 41.63 14.30 18 232268 17714 46436062
Sputum discoloured 41.14 14.30 7 232279 12771 46441005
Leukaemia 40.93 14.30 65 232221 3230 46450546
Cholestasis 40.89 14.30 44 232242 26849 46426927
Cholecystitis chronic 40.67 14.30 3 232283 10496 46443280
Respiratory depression 40.49 14.30 5 232281 11595 46442181
Altered state of consciousness 40.41 14.30 34 232252 23314 46430462
Psychotic disorder 40.32 14.30 32 232254 22589 46431187
Gastrointestinal haemorrhage 40.27 14.30 223 232063 77150 46376626
Protein total abnormal 40.26 14.30 24 232262 333 46453443
Product administration error 40.19 14.30 24 232262 19657 46434119
Jaundice 39.77 14.30 51 232235 28794 46424982
Hallucination 39.76 14.30 122 232164 49829 46403947
Iron deficiency anaemia 39.55 14.30 18 232268 17188 46436588
Rib fracture 39.54 14.30 193 232093 18761 46435015
Respiratory distress 39.46 14.30 61 232225 31855 46421921
Angina pectoris 39.40 14.30 45 232241 26730 46427046
Circulatory collapse 39.29 14.30 30 232256 21594 46432182
Blood urea increased 39.08 14.30 41 232245 25311 46428465
Complication associated with device 39 14.30 14 232272 15427 46438349
Product storage error 39.00 14.30 6 232280 11786 46441990
Transfusion 38.93 14.30 9 232277 13222 46440554
Accidental overdose 38.87 14.30 26 232260 20040 46433736
Drug resistance 38.65 14.30 19 232267 17349 46436427
Arthritis 38.53 14.30 226 232060 77090 46376686
Joint stiffness 38.35 14.30 47 232239 27061 46426715
Hypoxia 38.21 14.30 131 232155 51707 46402069
Failure to thrive 38.17 14.30 95 232191 6569 46447207
Muscle rigidity 38.15 14.30 3 232283 9958 46443818
Tachypnoea 38.01 14.30 12 232274 14339 46439437
Blood lactate dehydrogenase increased 37.81 14.30 28 232258 20472 46433304
Pericarditis 37.67 14.30 38 232248 23889 46429887
Dysphonia 37.65 14.30 323 231963 38091 46415685
Abortion induced 36.87 14.30 4 232282 10256 46443520
Gastritis 36.77 14.30 72 232214 34306 46419470
Impaired healing 36.72 14.30 80 232206 36663 46417113
Blood calcium decreased 36.66 14.30 165 232121 15508 46438268
Invasive ductal breast carcinoma 36.46 14.30 89 232197 6079 46447697
Disability 36.44 14.30 4 232282 10163 46443613
Palmar-plantar erythrodysaesthesia syndrome 36.36 14.30 29 232257 20422 46433354
Melaena 36.36 14.30 51 232235 27721 46426055
Vitamin B12 decreased 36.22 14.30 56 232230 2719 46451057
Blood calcium increased 36.16 14.30 101 232185 7486 46446290
Blood immunoglobulin G increased 36.10 14.30 37 232249 1177 46452599
Speech disorder 35.94 14.30 79 232207 36088 46417688
Wound 35.90 14.30 102 232184 42700 46411076
Skin cancer 35.88 14.30 111 232175 8712 46445064
Hypotension 35.85 14.30 882 231404 231707 46222069
Bone erosion 35.73 14.30 3 232283 9440 46444336
Bone marrow failure 35.39 14.30 261 232025 29408 46424368
Anosmia 34.90 14.30 67 232219 3877 46449899
Hypercalcaemia 34.80 14.30 201 232085 20845 46432931
Respiratory syncytial virus infection 34.34 14.30 75 232211 4760 46449016
Obstructive airways disorder 34.15 14.30 12 232274 13400 46440376
Body temperature decreased 34.14 14.30 12 232274 13397 46440379
Metastases to lung 34.13 14.30 6 232280 10690 46443086
Rales 33.99 14.30 4 232282 9627 46444149
Lethargy 33.99 14.30 135 232151 51036 46402740
Haematoma 33.87 14.30 67 232219 31805 46421971
Peritonitis 33.65 14.30 32 232254 20682 46433094
Ovarian cyst 33.55 14.30 14 232272 14073 46439703
Blood immunoglobulin A increased 33.21 14.30 22 232264 371 46453405
Panic attack 33.20 14.30 31 232255 20211 46433565
Therapeutic response decreased 33.19 14.30 107 232179 43038 46410738
Mitral valve incompetence 33.18 14.30 27 232259 18825 46434951
Blood pressure decreased 32.98 14.30 159 232127 57000 46396776
Pneumonia influenzal 32.77 14.30 39 232247 1470 46452306
Torsade de pointes 32.48 14.30 10 232276 12144 46441632
Pancreatitis 32.32 14.30 110 232176 43517 46410259
Hallucination, auditory 32.28 14.30 7 232279 10749 46443027
Urinary retention 32.03 14.30 50 232236 26011 46427765
Pain in jaw 31.78 14.30 92 232194 38280 46415496
Chronic lymphocytic leukaemia 31.70 14.30 54 232232 2846 46450930
Vertigo 31.67 14.30 142 232144 51906 46401870
Refractory cytopenia with multilineage dysplasia 31.54 14.30 15 232271 127 46453649
Malignant neoplasm of unknown primary site 31.48 14.30 19 232267 270 46453506
Transplant rejection 31.47 14.30 5 232281 9591 46444185
Nail discolouration 31.41 14.30 47 232239 2217 46451559
Middle insomnia 31.11 14.30 5 232281 9510 46444266
Eye infection 31.02 14.30 108 232178 9015 46444761
Chest pain 31.01 14.30 655 231631 175669 46278107
Post procedural complication 30.98 14.30 20 232266 15709 46438067
Hypokinesia 30.83 14.30 9 232277 11313 46442463
Ear swelling 30.77 14.30 32 232254 1036 46452740
Abdominal pain lower 30.73 14.30 36 232250 21145 46432631
Hypothyroidism 30.69 14.30 69 232217 31269 46422507
Upper respiratory tract infection 30.57 14.30 465 231821 63091 46390685
Tricuspid valve incompetence 30.53 14.30 15 232271 13702 46440074
Nausea 30.50 14.30 2977 229309 684477 45769299
White blood cell count increased 30.43 14.30 115 232171 44104 46409672
Gastrointestinal motility disorder 30.16 14.30 68 232218 4410 46449366
Osteonecrosis 30.14 14.30 51 232235 25693 46428083
POEMS syndrome 30.02 14.30 8 232278 6 46453770
Hepatic failure 30.01 14.30 77 232209 33339 46420437
Dry eye 29.73 14.30 255 232031 30067 46423709
Shock 29.73 14.30 39 232247 21806 46431970
Liver function test decreased 29.52 14.30 11 232275 46 46453730
Respiratory rate increased 29.51 14.30 10 232276 11423 46442353
Upper gastrointestinal haemorrhage 29.43 14.30 24 232262 16714 46437062
Pulmonary fibrosis 29.31 14.30 34 232252 20058 46433718
White blood cell disorder 29.28 14.30 42 232244 1906 46451870
Incorrect product administration duration 29.22 14.30 6 232280 9571 46444205
Schizophrenia 29.17 14.30 4 232282 8564 46445212
Hyperglycaemia 29.10 14.30 84 232202 34987 46418789
Mucosal inflammation 29.06 14.30 98 232188 38878 46414898
Food poisoning 28.99 14.30 54 232232 3054 46450722
Parkinsonism 28.81 14.30 3 232283 7945 46445831
Muscle strain 28.63 14.30 87 232199 6762 46447014
Myositis 28.61 14.30 3 232283 7901 46445875
Back pain 28.54 14.30 1298 230988 208741 46245035
Scar 28.53 14.30 12 232274 12007 46441769
Dysphagia 28.29 14.30 247 232039 77065 46376711
Tuberculosis 28.25 14.30 8 232278 10257 46443519
Breath sounds abnormal 28.20 14.30 3 232283 7812 46445964
Platelet count abnormal 28.19 14.30 50 232236 2722 46451054
Hepatic function abnormal 28.16 14.30 83 232203 34338 46419438
Uterine disorder 28.00 14.30 49 232237 2639 46451137
Aphasia 27.89 14.30 63 232223 28504 46425272
Neuralgia 27.76 14.30 192 232094 21191 46432585
Paraesthesia 27.71 14.30 773 231513 116664 46337112
Acute hepatic failure 27.29 14.30 20 232266 14701 46439075
Foot deformity 27.27 14.30 22 232264 15403 46438373
Diabetes mellitus inadequate control 27.14 14.30 16 232270 13198 46440578
Sleep disorder 27.09 14.30 130 232156 46665 46407111
Cardiogenic shock 26.98 14.30 25 232261 16359 46437417
Oral disorder 26.94 14.30 93 232193 7729 46446047
Myocardial ischaemia 26.81 14.30 15 232271 12734 46441042
Affect lability 26.71 14.30 4 232282 8016 46445760
Refractory anaemia with an excess of blasts 26.64 14.30 20 232266 415 46453361
Spinal disorder 26.43 14.30 94 232192 7930 46445846
Left ventricular dysfunction 26.41 14.30 9 232277 10246 46443530
Neurotoxicity 26.26 14.30 18 232268 13699 46440077
Posterior reversible encephalopathy syndrome 26.26 14.30 22 232264 15119 46438657
Blood triglycerides increased 26.05 14.30 13 232273 11770 46442006
Stomatitis 25.99 14.30 481 231805 67816 46385960
Helicobacter infection 25.87 14.30 13 232273 11723 46442053
Hysterectomy 25.75 14.30 4 232282 7802 46445974
Ventricular tachycardia 25.53 14.30 28 232258 16939 46436837
Rhinorrhoea 25.39 14.30 355 231931 47310 46406466
Metastases to central nervous system 25.39 14.30 12 232274 11209 46442567
Mood swings 25.37 14.30 26 232260 16226 46437550
Red cell distribution width increased 25.29 14.30 4 232282 7700 46446076
Delusion 25.26 14.30 12 232274 11176 46442600
Proteinuria 25.25 14.30 27 232259 16526 46437250
Spinal osteoarthritis 25.24 14.30 20 232266 14131 46439645
Eczema 25.21 14.30 39 232247 20361 46433415
Blood calcium abnormal 25.14 14.30 26 232260 836 46452940
Shock haemorrhagic 25.11 14.30 6 232280 8618 46445158
Cholecystectomy 24.97 14.30 7 232279 9035 46444741
Ventricular fibrillation 24.94 14.30 13 232273 11483 46442293
Colitis 24.92 14.30 290 231996 37057 46416719
Protein total decreased 24.84 14.30 72 232214 5451 46448325
Angina unstable 24.60 14.30 4 232282 7544 46446232
Viral infection 24.46 14.30 244 232042 29991 46423785
Feeding disorder 24.35 14.30 108 232178 10086 46443690
Hepatic encephalopathy 24.34 14.30 10 232276 10147 46443629
Thrombophlebitis superficial 24.24 14.30 67 232219 4936 46448840
Blood magnesium abnormal 24.21 14.30 19 232267 422 46453354
Injection site discolouration 24.07 14.30 3 232283 6907 46446869
Cardiomegaly 24.01 14.30 31 232255 17451 46436325
Lacrimation increased 23.99 14.30 148 232138 15713 46438063
Asthma 23.99 14.30 316 231970 91226 46362550
Rash macular 23.87 14.30 171 232115 19089 46434687
Allergic sinusitis 23.86 14.30 20 232266 489 46453287
Nervousness 23.62 14.30 231 232055 28244 46425532
Chills 23.55 14.30 336 231950 95696 46358080
Tooth infection 23.44 14.30 122 232164 12164 46441612
Hypotonia 23.42 14.30 6 232280 8223 46445553
Therapy cessation 23.42 14.30 62 232224 26567 46427209
Productive cough 23.31 14.30 152 232134 50563 46403213
Uveitis 23.29 14.30 7 232279 8634 46445142
Hemiparesis 23.27 14.30 40 232246 20029 46433747
Anuria 23.25 14.30 14 232272 11417 46442359
Basal cell carcinoma 23.18 14.30 178 232108 20309 46433467
Photophobia 23.01 14.30 23 232263 14521 46439255
Miosis 22.92 14.30 3 232283 6654 46447122
Pulseless electrical activity 22.91 14.30 4 232282 7163 46446613
Eyelid cyst 22.80 14.30 6 232280 4 46453772
Metastases to lymph nodes 22.80 14.30 3 232283 6628 46447148
Pseudomonas infection 22.75 14.30 10 232276 9748 46444028
Sinus bradycardia 22.73 14.30 21 232265 13761 46440015
Ejection fraction decreased 22.44 14.30 34 232252 17903 46435873
Illness 22.38 14.30 120 232166 12104 46441672
Chondrocalcinosis pyrophosphate 22.37 14.30 26 232260 955 46452821
Pelvic fracture 22.31 14.30 115 232171 11424 46442352
Irritability 22.12 14.30 72 232214 28874 46424902
Restlessness 22.02 14.30 60 232226 25464 46428312
Post procedural haemorrhage 21.95 14.30 5 232281 7421 46446355
Influenza like illness 21.92 14.30 182 232104 57388 46396388
Cellulitis 21.75 14.30 480 231806 69808 46383968
Blood pressure abnormal 21.73 14.30 119 232167 12098 46441678
Tremor 21.64 14.30 740 231546 114899 46338877
Optic neuritis 21.61 14.30 4 232282 6867 46446909
Tubulointerstitial nephritis 21.60 14.30 25 232261 14763 46439013
Disease complication 21.57 14.30 47 232239 2978 46450798
Bronchospasm 21.42 14.30 28 232258 15679 46438097
Grip strength decreased 21.40 14.30 8 232278 8598 46445178
Skin necrosis 21.39 14.30 8 232278 8596 46445180
Lipase increased 21.39 14.30 8 232278 8595 46445181
Joint effusion 21.34 14.30 17 232269 11978 46441798
Atelectasis 21.29 14.30 38 232248 18752 46435024
Glycosylated haemoglobin increased 21.19 14.30 14 232272 10862 46442914
Osteoporosis 21.14 14.30 117 232169 40491 46413285
Lymphopenia 21.12 14.30 27 232259 15266 46438510
Platelet disorder 21.05 14.30 32 232254 1531 46452245
Peripheral coldness 21.02 14.30 101 232185 9754 46444022
Mouth ulceration 21.02 14.30 66 232220 26766 46427010
Large intestine infection 20.96 14.30 31 232255 1447 46452329
Bursitis 20.84 14.30 42 232244 19800 46433976
Major depression 20.81 14.30 4 232282 6686 46447090
Haemodialysis 20.63 14.30 10 232276 9207 46444569
Acute respiratory failure 20.56 14.30 75 232211 29063 46424713
Endometrial adenocarcinoma 20.49 14.30 27 232259 1130 46452646
Osteopenia 20.41 14.30 33 232253 16928 46436848
Rectal adenocarcinoma 20.39 14.30 20 232266 603 46453173
Oliguria 20.39 14.30 9 232277 8750 46445026
Swelling 20.30 14.30 468 231818 124043 46329733
Nightmare 20.25 14.30 32 232254 16566 46437210
Skin hyperpigmentation 20.15 14.30 65 232221 5217 46448559
Coordination abnormal 20.13 14.30 15 232271 10934 46442842
Movement disorder 20.07 14.30 33 232253 16816 46436960
Low density lipoprotein increased 19.96 14.30 3 232283 5997 46447779
Device failure 19.78 14.30 3 232283 5956 46447820
Gastrooesophageal reflux disease 19.71 14.30 256 232030 74088 46379688
Apnoea 19.68 14.30 6 232280 7333 46446443
Arteriosclerosis coronary artery 19.59 14.30 8 232278 8148 46445628
Hydronephrosis 19.54 14.30 9 232277 8536 46445240
Performance status decreased 19.44 14.30 47 232239 3190 46450586
Brain oedema 19.43 14.30 20 232266 12458 46441318
Disorientation 19.42 14.30 106 232180 36812 46416964
Cerebral infarction 19.36 14.30 56 232230 23310 46430466
Oesophageal squamous cell carcinoma 19.35 14.30 10 232276 103 46453673
Pyelonephritis 19.32 14.30 29 232257 15328 46438448
Muscular weakness 19.26 14.30 331 231955 91513 46362263
Product dispensing error 19.22 14.30 11 232275 9222 46444554
Plasma cell myeloma in remission 19.21 14.30 5 232281 3 46453773
Muscle twitching 19.15 14.30 27 232259 14645 46439131
Chalazion 19.09 14.30 14 232272 280 46453496
Ataxia 18.82 14.30 25 232261 13905 46439871
Night sweats 18.81 14.30 213 232073 27037 46426739
Tardive dyskinesia 18.78 14.30 7 232279 7536 46446240
Hypersensitivity 18.76 14.30 587 231699 149734 46304042
Carcinoid tumour of the appendix 18.70 14.30 6 232280 14 46453762
Pleural effusion 18.69 14.30 295 231991 82657 46371119
Mania 18.52 14.30 16 232270 10830 46442946
Disseminated intravascular coagulation 18.48 14.30 42 232244 18963 46434813
Respiratory acidosis 18.45 14.30 4 232282 6144 46447632
Haematuria 18.38 14.30 70 232216 26788 46426988
Target skin lesion 18.36 14.30 9 232277 82 46453694
Physical deconditioning 18.34 14.30 14 232272 298 46453478
Swollen tongue 18.24 14.30 79 232207 29153 46424623
Polyarthritis 18.19 14.30 5 232281 6537 46447239
Superficial spreading melanoma stage unspecified 18.03 14.30 10 232276 120 46453656
Gingival pain 18.00 14.30 69 232217 6034 46447742
Kidney infection 17.96 14.30 144 232142 16645 46437131
Amenorrhoea 17.95 14.30 11 232275 8884 46444892
Parainfluenzae virus infection 17.91 14.30 32 232254 1752 46452024
Spinal operation 17.91 14.30 3 232283 5537 46448239
Gastrointestinal fungal infection 17.85 14.30 13 232273 257 46453519
Myeloma cast nephropathy 17.75 14.30 10 232276 124 46453652
Motor dysfunction 17.73 14.30 7 232279 7275 46446501
Blood pressure diastolic increased 17.70 14.30 4 232282 5970 46447806
Renal injury 17.64 14.30 13 232273 9528 46444248
Sensory disturbance 17.63 14.30 21 232265 12246 46441530
Malignant melanoma in situ 17.47 14.30 21 232265 800 46452976
Throat tightness 17.44 14.30 49 232237 20590 46433186
Epstein-Barr virus infection 17.39 14.30 6 232280 6778 46446998
Deafness 17.29 14.30 138 232148 15930 46437846
Lentigo maligna 17.26 14.30 11 232275 173 46453603
Viral upper respiratory tract infection 17.26 14.30 75 232211 6943 46446833
Red blood cell count abnormal 17.25 14.30 22 232264 891 46452885
Precursor B-lymphoblastic lymphoma 17.20 14.30 5 232281 7 46453769
Oral herpes 17.16 14.30 45 232241 19345 46434431
Acute generalised exanthematous pustulosis 17.15 14.30 13 232273 9392 46444384
Oedema 17.03 14.30 233 232053 66838 46386938
Cushingoid 17.03 14.30 5 232281 6261 46447515
Colon cancer 16.97 14.30 91 232195 9178 46444598
Laryngeal oedema 16.93 14.30 3 232283 5316 46448460
Localised infection 16.86 14.30 187 232099 23614 46430162
Pain in extremity 16.85 14.30 1085 231201 257595 46196181
Hepatic cirrhosis 16.78 14.30 33 232253 15699 46438077
Folliculitis 16.76 14.30 5 232281 6198 46447578
Central nervous system lesion 16.64 14.30 14 232272 9601 46444175
Gingival bleeding 16.61 14.30 107 232179 11532 46442244
Abdominal discomfort 16.59 14.30 600 231686 150565 46303211
Brain injury 16.54 14.30 5 232281 6145 46447631
Nystagmus 16.52 14.30 4 232282 5695 46448081
Genital haemorrhage 16.50 14.30 6 232280 6560 46447216
Pemphigoid 16.49 14.30 4 232282 5687 46448089
Disturbance in attention 16.39 14.30 91 232195 31469 46422307
Uterine leiomyoma 16.36 14.30 10 232276 8089 46445687
Blood lactic acid increased 16.34 14.30 4 232282 5653 46448123
Paraproteinaemia 16.34 14.30 10 232276 146 46453630
Nasal abscess 16.34 14.30 10 232276 146 46453630
Anger 16.29 14.30 21 232265 11831 46441945
Pneumothorax 16.20 14.30 30 232256 14599 46439177
Pharyngitis 16.19 14.30 40 232246 17543 46436233
Activated partial thromboplastin time prolonged 16.16 14.30 7 232279 6882 46446894
Breast cancer metastatic 16.10 14.30 27 232259 13651 46440125
Deformity 16.05 14.30 8 232278 7249 46446527
Fistula 16.03 14.30 10 232276 8000 46445776
Clavicle fracture 15.99 14.30 41 232245 2888 46450888
Duodenal ulcer 15.90 14.30 8 232278 7210 46446566
Sternal fracture 15.87 14.30 28 232258 1518 46452258
Arteriosclerosis 15.85 14.30 15 232271 9718 46444058
Pneumonitis 15.84 14.30 80 232206 28340 46425436
Bundle branch block left 15.83 14.30 6 232280 6393 46447383
Hiatus hernia 15.80 14.30 43 232243 18259 46435517
Malignant melanoma 15.80 14.30 96 232190 10138 46443638
Bipolar disorder 15.74 14.30 8 232278 7169 46446607
Therapy non-responder 15.71 14.30 290 231996 40862 46412914
Device occlusion 15.69 14.30 5 232281 5940 46447836
Hypoaesthesia oral 15.64 14.30 98 232188 10461 46443315
Partial seizures 15.58 14.30 3 232283 5007 46448769
Visual acuity reduced 15.54 14.30 57 232229 22056 46431720
Amnesia 15.42 14.30 292 231994 41339 46412437
Gastroenteritis 15.39 14.30 65 232221 24154 46429622
Paranoia 15.38 14.30 18 232268 10579 46443197
Musculoskeletal disorder 15.38 14.30 131 232155 15414 46438362
Encephalitis 15.32 14.30 9 232277 7439 46446337
Liver function test increased 15.29 14.30 60 232226 22766 46431010
Pigmentation disorder 15.21 14.30 47 232239 3686 46450090
Acidosis 15.15 14.30 20 232266 11154 46442622
Bradyphrenia 15.15 14.30 6 232280 6224 46447552
Foreign body in respiratory tract 15.08 14.30 12 232274 272 46453504
Respiratory tract congestion 15.06 14.30 112 232174 12652 46441124
Hypertensive crisis 15.01 14.30 28 232258 13587 46440189
Gastric ulcer 14.95 14.30 57 232229 21806 46431970
Hyperbilirubinaemia 14.86 14.30 18 232268 10420 46443356
Cervical vertebral fracture 14.77 14.30 34 232252 2236 46451540
Balance disorder 14.73 14.30 423 231863 64098 46389678
Rhinitis allergic 14.71 14.30 8 232278 6900 46446876
Hypertriglyceridaemia 14.70 14.30 5 232281 5699 46448077
Infusion site extravasation 14.64 14.30 4 232282 5252 46448524
Eye movement disorder 14.63 14.30 3 232283 4790 46448986
Invasive lobular breast carcinoma 14.62 14.30 17 232269 625 46453151
Urethral cancer 14.48 14.30 4 232282 4 46453772
Bronchiectasis 14.43 14.30 15 232271 9301 46444475
Weight fluctuation 14.43 14.30 68 232218 6516 46447260
Urinary incontinence 14.42 14.30 83 232203 28447 46425329
Hepatomegaly 14.40 14.30 21 232265 11232 46442544

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plasma cell myeloma 12907.47 14.07 6873 226282 46589 29672734
Death 4492.91 14.07 9048 224107 348235 29371088
Full blood count decreased 4080.79 14.07 2128 231027 13589 29705734
Thrombosis 2914.97 14.07 2502 230653 39729 29679594
Pneumonia 2600.44 14.07 7029 226126 327277 29392046
Neuropathy peripheral 2344.94 14.07 2813 230342 67662 29651661
White blood cell count decreased 2090.40 14.07 2903 230252 81044 29638279
Laboratory test abnormal 1908.18 14.07 1358 231797 16084 29703239
Platelet count decreased 1781.10 14.07 3058 230097 103071 29616252
Adverse drug reaction 1705.48 14.07 1425 231730 21720 29697603
Unevaluable event 1530.50 14.07 1542 231613 30243 29689080
Rash 1497.58 14.07 4050 229105 187839 29531484
Fatigue 1389.79 14.07 5536 227619 315137 29404186
Drug interaction 1237.88 14.07 81 233074 199487 29519836
Deep vein thrombosis 1026.83 14.07 1754 231401 58747 29660576
Off label use 969.35 14.07 366 232789 248924 29470399
Myelodysplastic syndrome 881.43 14.07 899 232256 17879 29701444
Plasma cell myeloma recurrent 791.18 14.07 429 232726 2985 29716338
Constipation 722.64 14.07 2223 230932 110683 29608640
Diarrhoea 713.43 14.07 4736 228419 329367 29389956
Muscle spasms 686.09 14.07 1541 231614 63297 29656026
Completed suicide 626.11 14.07 37 233118 99455 29619868
Drug abuse 615.43 14.07 4 233151 82068 29637255
Cardiac disorder 595.53 14.07 1094 232061 38799 29680524
Tooth disorder 569.02 14.07 512 232643 8649 29710674
Condition aggravated 518.95 14.07 212 232943 137654 29581669
Overdose 470.90 14.07 53 233102 84284 29635039
Neutropenia 458.55 14.07 2098 231057 126442 29592881
Drug ineffective 455.74 14.07 1262 231893 339125 29380198
Drug intolerance 453.90 14.07 1054 232101 44237 29675086
Plasmacytoma 434.32 14.07 290 232865 3066 29716257
Pancytopenia 433.13 14.07 1551 231604 83501 29635822
Pulmonary thrombosis 432.88 14.07 374 232781 5969 29713354
Squamous cell carcinoma of skin 414.98 14.07 429 232726 8666 29710657
Renal disorder 407.71 14.07 690 232465 22894 29696429
Influenza 403.52 14.07 981 232174 42417 29676906
Peripheral swelling 401.65 14.07 1215 231940 59859 29659464
Product dose omission issue 401.13 14.07 1592 231563 90039 29629284
Pulmonary embolism 385.15 14.07 1410 231745 76725 29642598
Ageusia 379.42 14.07 406 232749 8547 29710776
COVID-19 355.05 14.07 557 232598 17321 29702002
Rash pruritic 350.61 14.07 630 232525 21942 29697381
Red blood cell count decreased 329.18 14.07 670 232485 25651 29693672
Blood count abnormal 316.20 14.07 421 232734 11231 29708092
Product use in unapproved indication 311.93 14.07 93 233062 73600 29645723
Neutrophil count decreased 308.10 14.07 875 232280 41579 29677744
Intentional overdose 306.08 14.07 3 233152 41478 29677845
Blood test abnormal 304.70 14.07 289 232866 5236 29714087
Alanine aminotransferase increased 303.20 14.07 100 233055 74176 29645147
Rhabdomyolysis 298.36 14.07 65 233090 63515 29655808
Aspartate aminotransferase increased 291.27 14.07 68 233087 63354 29655969
Acute kidney injury 290.47 14.07 1124 232031 272718 29446605
Acute myeloid leukaemia 282.74 14.07 505 232650 17501 29701822
Body height decreased 276.98 14.07 231 232924 3503 29715820
Headache 274.79 14.07 635 232520 181671 29537652
Rheumatoid arthritis 266.22 14.07 13 233142 41184 29678139
Cytopenia 264.55 14.07 324 232831 7932 29711391
Cataract 263.80 14.07 548 232607 21287 29698036
Adult T-cell lymphoma/leukaemia 262.93 14.07 93 233062 173 29719150
Thrombocytopenia 252.90 14.07 1879 231276 135165 29584158
Taste disorder 251.19 14.07 212 232943 3271 29716052
Blood creatine phosphokinase increased 248.59 14.07 26 233129 43822 29675501
Asthenia 248.19 14.07 2722 230433 218568 29500755
Seasonal allergy 245.83 14.07 240 232915 4513 29714810
Intentional product misuse 245.06 14.07 5 233150 34662 29684661
Back disorder 242.03 14.07 265 232890 5729 29713594
Plasma cell leukaemia 239.00 14.07 125 233030 800 29718523
Suicide attempt 238.99 14.07 11 233144 36686 29682637
Hospitalisation 237.11 14.07 32 233123 44287 29675036
Hypertension 235.19 14.07 363 232792 120991 29598332
Vomiting 234.92 14.07 899 232256 218919 29500404
Hyperkalaemia 234.63 14.07 110 233045 65900 29653423
Tachycardia 232.66 14.07 143 233012 73596 29645727
Light chain analysis increased 227.52 14.07 125 233030 895 29718428
Hip fracture 220.03 14.07 346 232809 10778 29708545
Hypoglycaemia 218.14 14.07 63 233092 50918 29668405
Abdominal pain 217.82 14.07 456 232699 135198 29584125
Full blood count increased 214.89 14.07 112 233043 711 29718612
Mantle cell lymphoma 206.25 14.07 136 233019 1405 29717918
Bradycardia 201.30 14.07 131 233024 65395 29653928
Injection site pain 197.65 14.07 9 233146 30301 29689022
Wrong technique in product usage process 197.61 14.07 11 233144 31144 29688179
Multiple allergies 196.17 14.07 150 233005 1993 29717330
Infection 195.02 14.07 1155 232000 76919 29642404
Hiccups 192.95 14.07 298 232857 9136 29710187
Gallbladder disorder 192.44 14.07 233 232922 5634 29713689
Depressed level of consciousness 192.11 14.07 33 233122 38189 29681134
Diffuse large B-cell lymphoma 191.12 14.07 269 232886 7572 29711751
Intentional product use issue 190.96 14.07 28 233127 36412 29682911
Psoriasis 190.38 14.07 48 233107 42458 29676865
Hyponatraemia 183.55 14.07 152 233003 67050 29652273
Agitation 183.24 14.07 96 233059 53977 29665346
Monoclonal immunoglobulin present 182.72 14.07 104 233051 804 29718519
Protein total increased 181.73 14.07 143 233012 1987 29717336
Haemoglobin decreased 176.65 14.07 1503 231652 112595 29606728
Suicidal ideation 173.33 14.07 35 233120 36079 29683244
Coma 173.01 14.07 50 233105 40399 29678924
Seizure 172.74 14.07 314 232841 98161 29621162
Inappropriate schedule of product administration 171.97 14.07 48 233107 39680 29679643
Aggression 168.56 14.07 40 233115 36867 29682456
Lactic acidosis 165.85 14.07 23 233132 31190 29688133
Blood pressure increased 164.85 14.07 190 232965 71738 29647585
Herpes zoster 162.43 14.07 558 232597 29385 29689938
Arthropathy 161.93 14.07 439 232716 20288 29699035
Blood potassium decreased 161.56 14.07 383 232772 16279 29703044
Metabolic acidosis 157.13 14.07 48 233107 37413 29681910
Interstitial lung disease 156.09 14.07 143 233012 60054 29659269
C-reactive protein increased 155.13 14.07 72 233083 43401 29675922
Cardio-respiratory arrest 153.56 14.07 132 233023 57174 29662149
Spinal fracture 153.46 14.07 224 232931 6524 29712799
Gastric disorder 150.72 14.07 284 232871 10259 29709064
Dry skin 148.62 14.07 448 232707 22006 29697317
Basal cell carcinoma 147.90 14.07 362 232793 15706 29703617
Renal failure 146.26 14.07 1591 231564 127375 29591948
Skin cancer 145.64 14.07 239 232916 7722 29711601
Product use issue 141.29 14.07 92 233063 45924 29673399
Electrocardiogram QT prolonged 139.71 14.07 52 233103 35783 29683540
Nasopharyngitis 136.98 14.07 855 232300 57994 29661329
Ascites 136.93 14.07 54 233101 35867 29683456
Bronchitis 130.53 14.07 627 232528 38498 29680825
Drug level increased 124.61 14.07 4 233151 18350 29700973
Hepatocellular injury 123.66 14.07 24 233131 25447 29693876
Gamma-glutamyltransferase increased 122.38 14.07 38 233117 29312 29690011
Myelodysplastic syndrome transformation 121.33 14.07 61 233094 355 29718968
Respiratory arrest 118.25 14.07 40 233115 29218 29690105
Hernia 118.03 14.07 229 232926 8457 29710866
Product quality issue 117.91 14.07 7 233148 18767 29700556
Skin discolouration 117.88 14.07 329 232826 15465 29703858
Oxygen saturation decreased 117.66 14.07 99 233056 43341 29675982
Depression 117.54 14.07 339 232816 90098 29629225
Blood alkaline phosphatase increased 117.30 14.07 49 233106 31438 29687885
Pruritus 117.25 14.07 1421 231734 116783 29602540
Therapeutic product effect incomplete 116.19 14.07 59 233096 33775 29685548
International normalised ratio increased 116.10 14.07 120 233035 47619 29671704
Incorrect dose administered 115.35 14.07 51 233104 31635 29687688
Anaphylactic reaction 113.54 14.07 38 233117 27944 29691379
Abnormal behaviour 112.68 14.07 30 233125 25593 29693730
Melaena 112.24 14.07 56 233099 32381 29686942
Swelling face 110.51 14.07 390 232765 20814 29698509
Fall 109.57 14.07 2006 231149 179866 29539457
Localised infection 109.35 14.07 293 232862 13444 29705879
Spinal disorder 108.69 14.07 133 233022 3252 29716071
Hypercalcaemia 108.15 14.07 275 232880 12220 29707103
SARS-CoV-2 test positive 107.35 14.07 94 233061 1528 29717795
Hypoaesthesia 106.91 14.07 756 232399 53474 29665849
Dysarthria 106.46 14.07 52 233103 30438 29688885
Hepatic function abnormal 105.94 14.07 102 233053 41843 29677480
Medication error 105.61 14.07 18 233137 20954 29698369
Disease progression 105.52 14.07 1017 232138 78857 29640466
Somnolence 104.18 14.07 394 232761 96369 29622954
Adenocarcinoma of colon 103.53 14.07 128 233027 3164 29716159
Amyloidosis 103.19 14.07 104 233051 2035 29717288
Sedation 103.15 14.07 6 233149 16367 29702956
Cholestasis 102.78 14.07 33 233122 24917 29694406
Tumour flare 102.72 14.07 59 233096 465 29718858
Acute leukaemia 102.67 14.07 79 233076 1060 29718263
Angioedema 102.52 14.07 71 233084 34313 29685010
Generalised tonic-clonic seizure 102.47 14.07 15 233140 19536 29699787
Haematuria 102.07 14.07 119 233036 44715 29674608
Blood urea increased 101.52 14.07 59 233096 31322 29688001
Compression fracture 100.79 14.07 120 233035 2849 29716474
Immune system disorder 100.20 14.07 144 233011 4133 29715190
Product prescribing error 99.96 14.07 8 233147 16725 29702598
Upper limb fracture 99.89 14.07 141 233014 3979 29715344
Lactose intolerance 99.32 14.07 69 233086 782 29718541
Blood bilirubin increased 97.38 14.07 85 233070 36551 29682772
Musculoskeletal disorder 96.57 14.07 152 233003 4737 29714586
Hypoacusis 96.29 14.07 285 232870 13854 29705469
5q minus syndrome 95.87 14.07 39 233116 124 29719199
Psychotic disorder 94.97 14.07 25 233130 21490 29697833
Gastrointestinal haemorrhage 94.95 14.07 332 232823 83114 29636209
Rib fracture 93.97 14.07 264 232891 12456 29706867
Mucosal inflammation 93.55 14.07 61 233094 30433 29688890
Hallucination, visual 92.75 14.07 9 233146 16104 29703219
Atrial fibrillation 92.47 14.07 1265 231890 106859 29612464
Drug-induced liver injury 91.50 14.07 26 233129 21248 29698075
Hallucination 90.90 14.07 151 233004 48908 29670415
Emotional distress 90.23 14.07 9 233146 15756 29703567
Shock 89.38 14.07 33 233122 22826 29696497
Eye disorder 88.61 14.07 190 232965 7544 29711779
Epilepsy 87.96 14.07 24 233131 20145 29699178
Drug hypersensitivity 87.43 14.07 259 232896 68260 29651063
Cardiac arrest 86.93 14.07 399 232756 92451 29626872
Transaminases increased 86.57 14.07 37 233118 23420 29695903
Pallor 86.42 14.07 28 233127 21021 29698302
Wheezing 85.64 14.07 69 233086 30869 29688454
Anxiety 85.45 14.07 384 232771 89487 29629836
Accidental overdose 85.04 14.07 19 233136 18256 29701067
Erythema 84.24 14.07 314 232841 77137 29642186
Leukocytosis 84.14 14.07 31 233124 21471 29697852
Drug resistance 84.05 14.07 26 233129 20107 29699216
Myoclonus 83.49 14.07 5 233150 13307 29706016
Dehydration 83.40 14.07 1388 231767 122151 29597172
Blood calcium increased 82.90 14.07 111 233044 2976 29716347
Hepatic failure 82.28 14.07 86 233069 33957 29685366
Agranulocytosis 81.96 14.07 34 233121 21908 29697415
Bone pain 81.77 14.07 329 232826 18697 29700626
Dysgeusia 81.65 14.07 396 232759 24405 29694918
Dyskinesia 81.29 14.07 34 233121 21800 29697523
Upper gastrointestinal haemorrhage 80.89 14.07 35 233120 21993 29697330
Pregnancy of partner 80.79 14.07 42 233113 265 29719058
Pancreatitis acute 80.74 14.07 50 233105 25645 29693678
Back pain 80.37 14.07 1182 231973 101414 29617909
Spinal compression fracture 78.25 14.07 159 232996 6075 29713248
Sepsis 77.95 14.07 1585 231570 144810 29574513
Prostatic disorder 77.86 14.07 102 233053 2676 29716647
Diabetic ketoacidosis 77.73 14.07 15 233140 15971 29703352
Pancreatitis 77.65 14.07 102 233053 36388 29682935
Delirium 76.25 14.07 124 233031 40507 29678816
Pathological fracture 75.65 14.07 124 233031 4002 29715321
Unresponsive to stimuli 75.56 14.07 57 233098 26362 29692961
Peritonitis bacterial 75.43 14.07 3 233152 11375 29707948
Underdose 74.83 14.07 5 233150 12136 29707187
Gout 73.28 14.07 298 232857 17017 29702306
Jaundice 73.11 14.07 87 233068 32399 29686924
Gastrointestinal disorder 72.56 14.07 420 232735 27717 29691606
Sinus tachycardia 72.38 14.07 16 233139 15488 29703835
Asthma 72.09 14.07 106 233049 36068 29683255
Incorrect route of product administration 71.73 14.07 4 233151 11311 29708012
Encephalopathy 71.67 14.07 87 233068 32118 29687205
Coronary artery disease 71.61 14.07 177 232978 49535 29669788
Hypoxia 70.02 14.07 169 232986 47685 29671638
General physical health deterioration 69.81 14.07 473 232682 99471 29619852
Tubulointerstitial nephritis 69.66 14.07 26 233129 17865 29701458
Joint swelling 69.66 14.07 613 232542 46333 29672990
Cerebral infarction 69.10 14.07 62 233093 26311 29693012
Leukaemia 68.61 14.07 105 233050 3192 29716131
Anaphylactic shock 68.31 14.07 13 233142 13980 29705343
Palpitations 68.26 14.07 97 233058 33476 29685847
White blood cell count increased 68.16 14.07 128 233027 39545 29679778
Fear 68.09 14.07 4 233151 10821 29708502
Blood pressure systolic increased 67.76 14.07 17 233138 15093 29704230
Respiratory depression 67.34 14.07 6 233149 11497 29707826
Malignant melanoma 67.16 14.07 166 232989 7245 29712078
Acute lymphocytic leukaemia 67 14.07 100 233055 2972 29716351
Blood creatinine increased 66.05 14.07 428 232727 90947 29628376
Mobility decreased 65.90 14.07 63 233092 25936 29693387
Arthralgia 65.54 14.07 708 232447 135083 29584240
Vitamin D decreased 65.05 14.07 91 233064 2546 29716777
Malignant neoplasm of unknown primary site 65.02 14.07 39 233116 336 29718987
Hepatitis 64.23 14.07 48 233107 22308 29697015
Multiple organ dysfunction syndrome 64.16 14.07 265 232890 63222 29656101
Cardiac amyloidosis 64.08 14.07 51 233104 721 29718602
Circulatory collapse 63.98 14.07 39 233116 20175 29699148
Myalgia 63.96 14.07 343 232812 76324 29642999
Confusional state 63.88 14.07 706 232449 134128 29585195
Bone disorder 63.23 14.07 153 233002 6588 29712735
Anaemia 63.16 14.07 2090 231065 205902 29513421
Cyanosis 62.91 14.07 9 233146 11926 29707397
Withdrawal syndrome 62.90 14.07 7 233148 11243 29708080
Palmar-plantar erythrodysaesthesia syndrome 62.44 14.07 19 233136 14851 29704472
Nausea 62.39 14.07 1798 231357 295159 29424164
Altered state of consciousness 62.25 14.07 39 233116 19880 29699443
Hepatic encephalopathy 61.68 14.07 17 233138 14175 29705148
Brain oedema 61.64 14.07 11 233144 12387 29706936
Status epilepticus 61.63 14.07 7 233148 11065 29708258
Ventricular tachycardia 61.45 14.07 57 233098 23805 29695518
Colitis ulcerative 61.41 14.07 18 233137 14416 29704907
Sinus disorder 61.31 14.07 144 233011 6081 29713242
Increased tendency to bruise 60.82 14.07 104 233051 3477 29715846
Paranoia 60.50 14.07 5 233150 10183 29709140
Liver function test abnormal 60.40 14.07 92 233063 30858 29688465
Drug ineffective for unapproved indication 60.25 14.07 7 233148 10873 29708450
Haematemesis 60.22 14.07 69 233086 26134 29693189
Bone lesion 60.12 14.07 88 233067 2569 29716754
Neutrophil count increased 60.11 14.07 22 233133 15301 29704022
Blood lactate dehydrogenase increased 59.49 14.07 44 233111 20557 29698766
White blood cell count abnormal 59.39 14.07 88 233067 2598 29716725
Cytomegalovirus infection 59.27 14.07 58 233097 23616 29695707
Renal injury 59.20 14.07 10 233145 11719 29707604
Transplant rejection 59.15 14.07 3 233152 9203 29710120
Hypokalaemia 58.21 14.07 198 232957 49994 29669329
Obstructive airways disorder 58.06 14.07 3 233152 9056 29710267
Hypotension 57.90 14.07 1157 231998 199408 29519915
Arteriosclerosis coronary artery 57.59 14.07 9 233146 11167 29708156
Hepatotoxicity 57.44 14.07 35 233120 18110 29701213
Adverse event 57.15 14.07 254 232901 15087 29704236
Respiratory distress 56.97 14.07 106 233049 32866 29686457
Blood triglycerides increased 56.92 14.07 19 233136 13998 29705325
Illness 56.39 14.07 96 233059 3198 29716125
Hyperlipidaemia 56.21 14.07 19 233136 13888 29705435
Osteonecrosis of jaw 56.13 14.07 290 232865 18328 29700995
Surgery 55.82 14.07 11 233144 11540 29707783
Hemiparesis 55.18 14.07 23 233132 14779 29704544
Delusion 54.71 14.07 13 233142 11976 29707347
Chronic lymphocytic leukaemia 54.52 14.07 115 233040 4513 29714810
Tachypnoea 54.51 14.07 24 233131 14928 29704395
Hypogeusia 54.13 14.07 48 233107 794 29718529
Injection site erythema 54.03 14.07 20 233135 13814 29705509
Hyperhidrosis 53.85 14.07 304 232851 66786 29652537
Malignant neoplasm progression 53.55 14.07 336 232819 71951 29647372
Chest discomfort 53.02 14.07 179 232976 45301 29674022
Injection site swelling 53.00 14.07 4 233151 8776 29710547
Coagulopathy 52.72 14.07 40 233115 18447 29700876
Product administration error 52.54 14.07 23 233132 14354 29704969
Restlessness 52.49 14.07 59 233096 22540 29696783
Disseminated intravascular coagulation 52.47 14.07 57 233098 22114 29697209
Treatment noncompliance 52.29 14.07 72 233083 25181 29694142
Acute myocardial infarction 52.23 14.07 223 232932 52716 29666607
Hordeolum 52.06 14.07 44 233111 680 29718643
Hepatic steatosis 51.98 14.07 25 233130 14768 29704555
Dysphonia 51.64 14.07 288 232867 18744 29700579
Cardiogenic shock 51.34 14.07 34 233121 16827 29702496
Fluid retention 51.29 14.07 352 232803 24646 29694677
Angina unstable 51.20 14.07 16 233139 12294 29707029
Exposure during pregnancy 51.18 14.07 6 233149 9255 29710068
Vitamin B12 decreased 50.88 14.07 51 233104 991 29718332
Accidental exposure to product 50.23 14.07 9 233146 10106 29709217
Injury 50.18 14.07 57 233098 21674 29697649
Synovitis 50.14 14.07 8 233147 9775 29709548
Thrombophlebitis superficial 50.00 14.07 81 233074 2588 29716735
Drug reaction with eosinophilia and systemic symptoms 49.74 14.07 91 233064 28397 29690926
Pulmonary hypertension 49.57 14.07 45 233110 18991 29700332
Light chain analysis abnormal 49.56 14.07 19 233136 49 29719274
Respiratory failure 49.23 14.07 523 232632 100119 29619204
Angina pectoris 49.16 14.07 97 233058 29421 29689902
Diabetes mellitus inadequate control 48.93 14.07 19 233136 12743 29706580
Renal tubular necrosis 48.86 14.07 29 233126 15222 29704101
Dementia 48.46 14.07 209 232946 12252 29707071
Depressed mood 48.36 14.07 37 233118 16992 29702331
Ventricular fibrillation 48.20 14.07 29 233126 15109 29704214
Chest pain 48.03 14.07 636 232519 116991 29602332
Myositis 47.86 14.07 11 233144 10366 29708957
Platelet disorder 47.56 14.07 53 233102 1169 29718154
Rectal haemorrhage 47.55 14.07 128 233027 34811 29684512
Acute respiratory distress syndrome 47.53 14.07 68 233087 23404 29695919
Peritonitis 47.29 14.07 58 233097 21317 29698006
Schizophrenia 47.28 14.07 7 233148 9041 29710282
Inappropriate antidiuretic hormone secretion 47.23 14.07 15 233140 11407 29707916
Lipase increased 47.02 14.07 6 233149 8670 29710653
Pulmonary arterial hypertension 46.79 14.07 8 233147 9293 29710030
Dry eye 46.56 14.07 133 233022 6335 29712988
Hepatitis cholestatic 46.37 14.07 4 233151 7868 29711455
Sleep apnoea syndrome 46.14 14.07 38 233117 16819 29702504
Coronavirus infection 46.04 14.07 91 233064 3407 29715916
Blood pressure decreased 46.01 14.07 199 232956 46876 29672447
Nerve injury 45.96 14.07 83 233072 2900 29716423
Cardiomegaly 45.91 14.07 28 233127 14481 29704842
Stress 45.73 14.07 54 233101 20181 29699142
Dystonia 45.48 14.07 10 233145 9717 29709606
Acidosis 45.40 14.07 12 233143 10289 29709034
Pathogen resistance 45.13 14.07 6 233149 8404 29710919
Lymphoma 45.08 14.07 177 232978 9944 29709379
Loss of personal independence in daily activities 44.99 14.07 61 233094 21474 29697849
Lower limb fracture 44.84 14.07 93 233062 3606 29715717
Hypomagnesaemia 44.72 14.07 38 233117 16560 29702763
Hepatic enzyme increased 44.61 14.07 124 233031 33370 29685953
Pneumonia aspiration 44.51 14.07 148 233007 37632 29681691
Hyperbilirubinaemia 44.18 14.07 40 233115 16902 29702421
Haematoma 44.10 14.07 74 233081 23879 29695444
Kidney transplant rejection 43.73 14.07 4 233151 7505 29711818
Infusion related reaction 43.72 14.07 165 232990 40399 29678924
Toxic epidermal necrolysis 43.71 14.07 45 233110 17895 29701428
Blood pressure fluctuation 43.68 14.07 43 233112 17460 29701863
Anuria 43.64 14.07 13 233142 10303 29709020
Cerebral haemorrhage 43.62 14.07 122 233033 32765 29686558
Clostridium difficile infection 43.59 14.07 240 232915 15543 29703780
Protein total abnormal 43.15 14.07 29 233126 310 29719013
Balance disorder 43.00 14.07 454 232701 36039 29683284
Duodenal ulcer 42.76 14.07 12 233143 9889 29709434
Monoclonal immunoglobulin increased 42.65 14.07 16 233139 38 29719285
Hepatic cirrhosis 42.65 14.07 37 233118 15962 29703361
Anhedonia 42.54 14.07 7 233148 8362 29710961
Flushing 42.47 14.07 105 233050 29387 29689936
Haemodynamic instability 42.35 14.07 6 233149 8009 29711314
Weight fluctuation 42.24 14.07 92 233063 3692 29715631
Hyperthermia 42.23 14.07 13 233142 10086 29709237
No adverse event 42.09 14.07 44 233111 17375 29701948
Aphasia 41.70 14.07 54 233101 19385 29699938
Full blood count abnormal 41.60 14.07 47 233108 1053 29718270
Treatment failure 41.44 14.07 135 233020 34544 29684779
Torsade de pointes 41.42 14.07 4 233151 7186 29712137
Gastritis 41.41 14.07 58 233097 20140 29699183
Injection site haemorrhage 41.22 14.07 6 233149 7849 29711474
Decreased appetite 41.07 14.07 1489 231666 148421 29570902
Hepatitis C 41.06 14.07 26 233129 13179 29706144
Proteinuria 41.06 14.07 39 233116 16106 29703217
Device malfunction 40.75 14.07 7 233148 8104 29711219
Shock haemorrhagic 40.71 14.07 13 233142 9852 29709471
Oliguria 40.67 14.07 5 233150 7434 29711889
Adverse reaction 40.48 14.07 77 233078 2801 29716522
Speech disorder 40.43 14.07 81 233074 24431 29694892
Blood iron decreased 40.38 14.07 94 233061 3946 29715377
Haemodialysis 40.01 14.07 18 233137 11055 29708268
Venoocclusive liver disease 39.95 14.07 3 233152 6610 29712713
Injection site bruising 39.95 14.07 5 233150 7333 29711990
Blood loss anaemia 39.62 14.07 6 233149 7621 29711702
Obesity 39.59 14.07 9 233146 8546 29710777
Neurotoxicity 39.58 14.07 27 233128 13155 29706168
B-cell type acute leukaemia 39.56 14.07 26 233129 267 29719056
Hypercholesterolaemia 39.38 14.07 6 233149 7586 29711737
Skin exfoliation 39.38 14.07 312 232843 22860 29696463
Metastases to bone 39.37 14.07 13 233142 9645 29709678
Myocardial ischaemia 39.36 14.07 46 233109 17271 29702052
Metastases to lung 39.26 14.07 7 233148 7888 29711435
Disturbance in attention 39.24 14.07 70 233085 22059 29697264
Blood albumin decreased 38.87 14.07 25 233130 12567 29706756
Inflammation 38.77 14.07 70 233085 21956 29697367
Hallucination, auditory 38.49 14.07 14 233141 9775 29709548
Swelling 38.46 14.07 439 232716 35536 29683787
Basosquamous carcinoma of skin 38.42 14.07 11 233144 5 29719318
Dysphagia 38.24 14.07 271 232884 56427 29662896
Therapeutic response unexpected 38.06 14.07 11 233144 8892 29710431
Metastases to liver 37.98 14.07 23 233132 11942 29707381
Therapy non-responder 37.85 14.07 373 232782 29080 29690243
Malignant melanoma in situ 37.31 14.07 42 233113 937 29718386
Glomerular filtration rate decreased 37.26 14.07 21 233134 11341 29707982
Osteolysis 37.24 14.07 53 233102 1507 29717816
Acute hepatic failure 37.17 14.07 23 233132 11804 29707519
Hypothermia 37.08 14.07 14 233141 9553 29709770
Posterior reversible encephalopathy syndrome 36.78 14.07 11 233144 8696 29710627
Hypertriglyceridaemia 36.52 14.07 9 233146 8089 29711234
Respiratory rate increased 36.34 14.07 12 233143 8903 29710420
Hypertensive crisis 36.33 14.07 10 233145 8347 29710976
Body temperature decreased 35.99 14.07 15 233140 9640 29709683
Bronchospasm 35.53 14.07 18 233137 10320 29709003
Chills 35.32 14.07 376 232779 71962 29647361
Mitral valve incompetence 34.80 14.07 31 233124 13203 29706120
Activated partial thromboplastin time prolonged 34.73 14.07 9 233146 7819 29711504
Respiratory tract congestion 34.68 14.07 108 233047 5398 29713925
Refractory anaemia with an excess of blasts 34.68 14.07 27 233128 369 29718954
Mania 34.48 14.07 14 233141 9140 29710183
Gynaecomastia 34.47 14.07 11 233144 8340 29710983
Blood electrolytes decreased 34.21 14.07 26 233129 342 29718981
Injection site reaction 33.72 14.07 21 233134 10739 29708584
Weight decreased 33.62 14.07 1466 231689 149455 29569868
White blood cell disorder 33.59 14.07 45 233110 1207 29718116
Dyslipidaemia 33.49 14.07 3 233152 5724 29713599
Product storage error 33.27 14.07 5 233150 6386 29712937
Left ventricular dysfunction 33.22 14.07 13 233142 8678 29710645
Coordination abnormal 33.18 14.07 8 233147 7297 29712026
Haemorrhage intracranial 33.03 14.07 41 233114 14991 29704332
Hypokinesia 32.88 14.07 8 233147 7252 29712071
Rhinorrhoea 32.86 14.07 275 232880 20479 29698844
Blood immunoglobulin G increased 32.85 14.07 38 233117 874 29718449
Dyspnoea 32.80 14.07 2195 230960 331100 29388223
B-cell lymphoma 32.72 14.07 93 233062 4417 29714906
Liver injury 32.66 14.07 29 233126 12371 29706952
Left ventricular hypertrophy 32.48 14.07 5 233150 6273 29713050
Viral infection 32.45 14.07 216 232939 14969 29704354
Feeling abnormal 32.30 14.07 621 232534 56135 29663188
Lacrimation increased 32.30 14.07 124 233031 6892 29712431
Type 2 diabetes mellitus 32.25 14.07 35 233120 13587 29705736
Paraesthesia 32.15 14.07 598 232557 53729 29665594
Pneumonia viral 32.09 14.07 67 233088 2610 29716713
Tooth infection 31.94 14.07 101 233054 5090 29714233
Hepatitis acute 31.70 14.07 8 233147 7075 29712248
Oral disorder 31.68 14.07 86 233069 3976 29715347
Uveitis 31.68 14.07 3 233152 5474 29713849
Prostate cancer 31.56 14.07 305 232850 23652 29695671
Post procedural complication 31.40 14.07 27 233128 11699 29707624
Chondrocalcinosis pyrophosphate 31.37 14.07 34 233121 726 29718597
Multiple sclerosis 31.03 14.07 9 233146 7258 29712065
Disease recurrence 30.72 14.07 39 233116 14122 29705201
Aphonia 30.62 14.07 71 233084 2973 29716350
Memory impairment 30.53 14.07 432 232723 36742 29682581
Hyperviscosity syndrome 30.38 14.07 20 233135 206 29719117
Toothache 30.37 14.07 107 233048 5704 29713619
Nephropathy toxic 30.36 14.07 23 233132 10616 29708707
Impaired work ability 30.35 14.07 4 233151 5639 29713684
Femur fracture 30.29 14.07 125 233030 7184 29712139
Arteriosclerosis 30.17 14.07 24 233131 10809 29708514
Urinary tract infection 29.91 14.07 768 232387 72891 29646432
Cerebrovascular accident 29.81 14.07 856 232299 82621 29636702
Dyspnoea exertional 29.81 14.07 158 232997 35272 29684051
Viral upper respiratory tract infection 29.77 14.07 65 233090 2613 29716710
Product dispensing error 29.77 14.07 5 233150 5884 29713439
Hypovolaemic shock 29.76 14.07 7 233148 6493 29712830
Tricuspid valve incompetence 29.65 14.07 15 233140 8608 29710715
Blood calcium decreased 29.56 14.07 150 233005 9412 29709911
Joint range of motion decreased 29.46 14.07 5 233150 5840 29713483
Rectal adenocarcinoma 29.43 14.07 34 233121 781 29718542
Limb discomfort 29.41 14.07 144 233011 8906 29710417
Parkinsonism 29.26 14.07 10 233145 7259 29712064
Epstein-Barr virus infection 29.20 14.07 8 233147 6698 29712625
Limb injury 29.18 14.07 143 233012 8848 29710475
Cardiac valve disease 28.80 14.07 68 233087 2881 29716442
Upper respiratory tract infection 28.79 14.07 334 232821 27142 29692181
Subarachnoid haemorrhage 28.69 14.07 21 233134 9865 29709458
Pulmonary fibrosis 28.41 14.07 50 233105 15840 29703483
Vertebral lesion 28.39 14.07 17 233138 146 29719177
Tumour marker increased 28.33 14.07 27 233128 492 29718831
Dermatitis allergic 28.22 14.07 104 233051 5668 29713655
Prostate cancer stage II 28.20 14.07 19 233136 204 29719119
Haemoptysis 28.19 14.07 135 233020 30943 29688380
Hiatus hernia 28.11 14.07 10 233145 7080 29712243
Auditory disorder 28.01 14.07 17 233138 150 29719173
Granulocytopenia 27.92 14.07 7 233148 6219 29713104
Crying 27.83 14.07 5 233150 5604 29713719
Cardiac failure congestive 27.83 14.07 857 232298 83550 29635773
Ejection fraction decreased 27.82 14.07 47 233108 15128 29704195
Glycosylated haemoglobin increased 27.75 14.07 20 233135 9471 29709852
Sinus bradycardia 27.74 14.07 30 233125 11665 29707658
Iron deficiency anaemia 27.74 14.07 18 233137 9006 29710317
Ataxia 27.64 14.07 29 233126 11433 29707890
Disorientation 27.62 14.07 138 233017 31280 29688043
Eosinophilia 27.36 14.07 85 233070 22075 29697248
Blood lactic acid increased 27.25 14.07 6 233149 5824 29713499
Cardiac failure 27.17 14.07 471 232684 82947 29636376
Hepatomegaly 27.07 14.07 23 233132 10024 29709299
Flatulence 27.01 14.07 237 232918 17892 29701431
Myocarditis 26.87 14.07 23 233132 9988 29709335
Skin sensitisation 26.66 14.07 17 233138 165 29719158
POEMS syndrome 26.58 14.07 10 233145 24 29719299
Asphyxia 26.56 14.07 5 233150 5420 29713903
Nightmare 26.47 14.07 33 233122 12043 29707280
Refractory cytopenia with multilineage dysplasia 26.28 14.07 16 233139 142 29719181
Metastases to central nervous system 26.07 14.07 12 233143 7272 29712051
Device dislocation 26.04 14.07 4 233151 5027 29714296
Arthropod bite 25.95 14.07 57 233098 2301 29717022
Knee arthroplasty 25.90 14.07 6 233149 5624 29713699
Myelofibrosis 25.86 14.07 45 233110 1526 29717797
Post transplant lymphoproliferative disorder 25.75 14.07 5 233150 5301 29714022
Injection site pruritus 25.64 14.07 6 233149 5586 29713737
Transfusion 25.62 14.07 13 233142 7448 29711875
Sinusitis 25.60 14.07 383 232772 32962 29686361
Visual acuity reduced 25.59 14.07 53 233102 15793 29703530
Hypotonia 25.57 14.07 11 233144 6937 29712386
Neuralgia 25.54 14.07 154 233001 10312 29709011
Bronchopulmonary aspergillosis 25.45 14.07 35 233120 12249 29707074
Sputum discoloured 25.44 14.07 10 233145 6658 29712665
Subdural haematoma 25.44 14.07 70 233085 18902 29700421
Breath sounds abnormal 25.37 14.07 4 233151 4931 29714392
Lower gastrointestinal haemorrhage 25.36 14.07 15 233140 7889 29711434
Gingival pain 25.31 14.07 53 233102 2069 29717254
B precursor type acute leukaemia 25.27 14.07 13 233142 80 29719243
Cytokine release syndrome 25.25 14.07 24 233131 9909 29709414
Eye swelling 25.22 14.07 137 233018 8827 29710496
Dialysis 25.21 14.07 29 233126 10967 29708356
Fracture 25.12 14.07 103 233052 5903 29713420
Papule 25.10 14.07 67 233088 3066 29716257
Gait disturbance 25.07 14.07 420 232735 74357 29644966
Cardiomyopathy 25.01 14.07 50 233105 15093 29704230
Red blood cell count abnormal 24.95 14.07 26 233129 530 29718793
Middle insomnia 24.93 14.07 7 233148 5766 29713557
Coronary artery bypass 24.77 14.07 5 233150 5157 29714166
Drug eruption 24.76 14.07 63 233092 17463 29701860
Tendonitis 24.74 14.07 16 233139 8020 29711303
Haemophagocytic lymphohistiocytosis 24.49 14.07 24 233131 9767 29709556
Enterococcal infection 24.48 14.07 17 233138 8207 29711116
Rales 24.39 14.07 10 233145 6490 29712833
Osteoarthritis 24.38 14.07 68 233087 18281 29701042
Dermatitis acneiform 24.37 14.07 7 233148 5682 29713641
Blood pressure diastolic decreased 24.35 14.07 9 233146 6222 29713101
Jaw disorder 24.05 14.07 54 233101 2213 29717110
Oesophagitis 23.99 14.07 31 233124 11140 29708183
Motor dysfunction 23.96 14.07 8 233147 5894 29713429
Gastritis erosive 23.88 14.07 7 233148 5606 29713717
Pelvic fracture 23.87 14.07 53 233102 2155 29717168
Platelet count abnormal 23.73 14.07 55 233100 2302 29717021
Renal tubular disorder 23.70 14.07 5 233150 5001 29714322
Hydronephrosis 23.67 14.07 21 233134 8962 29710361
Pseudomonas infection 23.65 14.07 28 233127 10454 29708869
Atrial flutter 23.56 14.07 191 232964 14090 29705233
Cholecystitis infective 23.52 14.07 44 233111 1580 29717743
Parosmia 23.42 14.07 40 233115 1336 29717987
Right ventricular failure 23.41 14.07 17 233138 8019 29711304
Pneumonia influenzal 23.41 14.07 39 233116 1276 29718047
Lentigo maligna 23.36 14.07 18 233137 242 29719081
Oedema 23.25 14.07 218 232937 42775 29676548
Vitamin B complex deficiency 23.24 14.07 15 233140 149 29719174
Panic attack 23.23 14.07 20 233135 8661 29710662
Gastrointestinal motility disorder 23.19 14.07 53 233102 2198 29717125
Food poisoning 23.18 14.07 37 233118 1167 29718156
Prothrombin time prolonged 23.04 14.07 23 233132 9280 29710043
Stent placement 23.01 14.07 4 233151 4592 29714731
Adenovirus infection 23.01 14.07 3 233152 4265 29715058
Coronary artery stenosis 22.96 14.07 22 233133 9048 29710275
Ventricular hypertrophy 22.90 14.07 5 233150 4882 29714441
Necrosis 22.89 14.07 6 233149 5173 29714150
Apnoea 22.88 14.07 10 233145 6248 29713075
Eosinophil count increased 22.85 14.07 15 233140 7458 29711865
Post procedural haemorrhage 22.70 14.07 17 233138 7893 29711430
Clavicle fracture 22.62 14.07 49 233106 1959 29717364
Blood immunoglobulin M increased 22.55 14.07 16 233139 188 29719135
Adrenal insufficiency 22.51 14.07 29 233126 10434 29708889
Ischaemia 22.50 14.07 4 233151 4517 29714806
Acute respiratory failure 22.46 14.07 114 233041 25736 29693587
Procedural pain 22.42 14.07 6 233149 5103 29714220
Eczema 22.20 14.07 44 233111 13325 29705998
Cholangitis 22.09 14.07 17 233138 7785 29711538
Heart rate increased 21.96 14.07 194 232961 38527 29680796
Visceral leishmaniasis 21.91 14.07 23 233132 473 29718850
Amylase increased 21.89 14.07 9 233146 5832 29713491
Rash macular 21.87 14.07 147 233008 10220 29709103
Blood pressure abnormal 21.78 14.07 110 233045 6889 29712434
Cellulitis 21.76 14.07 497 232658 46287 29673036
Brain injury 21.70 14.07 8 233147 5540 29713783
Pulmonary congestion 21.67 14.07 39 233116 12248 29707075
Fluid overload 21.66 14.07 76 233079 19016 29700307
Idiopathic pulmonary fibrosis 21.61 14.07 3 233152 4066 29715257
Ischaemic cardiomyopathy 21.58 14.07 11 233144 6286 29713037
Hypoxic-ischaemic encephalopathy 21.55 14.07 5 233150 4682 29714641
Lymphocyte count decreased 21.52 14.07 76 233079 18979 29700344
Hyperglycaemia 21.47 14.07 173 232982 35027 29684296
Myeloma cast nephropathy 21.43 14.07 10 233145 48 29719275
Spinal cord compression 21.35 14.07 70 233085 3596 29715727
Hepatocellular carcinoma 21.33 14.07 26 233129 9584 29709739
Multiple fractures 21.27 14.07 38 233117 1316 29718007
Pulse absent 21.23 14.07 8 233147 5465 29713858
Anosmia 21.14 14.07 49 233106 2051 29717272
Tuberculosis 21.14 14.07 19 233136 8058 29711265
Atrioventricular block first degree 20.94 14.07 9 233146 5679 29713644
Neutrophil count abnormal 20.85 14.07 38 233117 1337 29717986
Klebsiella infection 20.82 14.07 14 233141 6873 29712450
Cervical vertebral fracture 20.80 14.07 44 233111 1730 29717593
Pneumonitis 20.63 14.07 127 233028 27327 29691996
Blood magnesium decreased 20.58 14.07 91 233064 5392 29713931
Orthopnoea 20.56 14.07 5 233150 4535 29714788
Acute graft versus host disease 20.47 14.07 10 233145 5854 29713469
Abdominal pain lower 20.39 14.07 23 233132 8775 29710548
Hypernatraemia 20.32 14.07 17 233138 7467 29711856
Hypertransaminasaemia 20.31 14.07 3 233152 3882 29715441
Cystitis haemorrhagic 20.31 14.07 6 233149 4781 29714542
Aspergillus infection 20.27 14.07 30 233125 10184 29709139
Portal hypertension 20.23 14.07 3 233152 3870 29715453
Hepatic necrosis 20.16 14.07 3 233152 3860 29715463
Aspiration 19.97 14.07 32 233123 10519 29708804
Paraproteinaemia 19.95 14.07 18 233137 305 29719018
Skin necrosis 19.92 14.07 6 233149 4721 29714602
Electrocardiogram ST segment elevation 19.91 14.07 5 233150 4437 29714886
Hypercapnia 19.88 14.07 3 233152 3821 29715502
Anger 19.87 14.07 35 233120 11085 29708238
Atelectasis 19.85 14.07 62 233093 16076 29703247
Blood chloride decreased 19.81 14.07 3 233152 3810 29715513
Productive cough 19.78 14.07 144 233011 29809 29689514
Chronic graft versus host disease 19.74 14.07 4 233151 4115 29715208
Mental status changes 19.63 14.07 189 232966 36890 29682433
Blood cholesterol increased 19.62 14.07 67 233088 16903 29702420
Therapeutic product effect decreased 19.58 14.07 139 233016 28937 29690386
Salivary hypersecretion 19.56 14.07 18 233137 7548 29711775
Partial seizures 19.49 14.07 3 233152 3764 29715559
Superficial spreading melanoma stage I 19.46 14.07 7 233148 14 29719309
Ketoacidosis 19.34 14.07 3 233152 3743 29715580
Pleural effusion 19.33 14.07 434 232721 73632 29645691
Brain herniation 19.30 14.07 3 233152 3737 29715586
Irritability 19.27 14.07 103 233052 22947 29696376
Cardiac murmur 19.21 14.07 15 233140 6819 29712504
Duodenitis 19.20 14.07 4 233151 4036 29715287
Bladder transitional cell carcinoma 19.19 14.07 52 233103 2401 29716922
Toxic encephalopathy 19.15 14.07 6 233149 4603 29714720
Device occlusion 19.10 14.07 12 233143 6108 29713215
Appendix disorder 19.09 14.07 23 233132 553 29718770
Euphoric mood 18.90 14.07 5 233150 4285 29715038
Skin plaque 18.75 14.07 3 233152 3659 29715664
Lymphocytic leukaemia 18.74 14.07 13 233142 147 29719176
Haematocrit decreased 18.67 14.07 151 233004 30548 29688775
Blood immunoglobulin A increased 18.65 14.07 17 233138 292 29719031
Lethargy 18.64 14.07 207 232948 39312 29680011
Bone loss 18.46 14.07 23 233132 573 29718750
Muscle strain 18.38 14.07 67 233088 3632 29715691
Haemolytic anaemia 18.35 14.07 31 233124 9979 29709344
Myopathy 18.31 14.07 34 233121 10552 29708771
Monocyte count increased 18.31 14.07 3 233152 3595 29715728
Scar 18.10 14.07 11 233144 5700 29713623
Musculoskeletal pain 17.99 14.07 154 233001 30786 29688537
Hyperthyroidism 17.88 14.07 22 233133 8076 29711247
Splenomegaly 17.87 14.07 50 233105 13430 29705893
Colon cancer 17.83 14.07 119 233036 8253 29711070
Light chain analysis decreased 17.75 14.07 6 233149 9 29719314
Immunoglobulins abnormal 17.75 14.07 6 233149 9 29719314
Tenosynovitis 17.73 14.07 3 233152 3512 29715811
Bladder transitional cell carcinoma stage 0 17.72 14.07 12 233143 130 29719193
Lung adenocarcinoma 17.70 14.07 71 233084 4028 29715295
Sternal fracture 17.69 14.07 22 233133 547 29718776
Gastrooesophageal reflux disease 17.68 14.07 163 232992 32092 29687231
Exercise tolerance decreased 17.66 14.07 4 233151 3808 29715515
Cardiac tamponade 17.66 14.07 7 233148 4637 29714686
BK virus infection 17.57 14.07 6 233149 4358 29714965
Intracranial pressure increased 17.56 14.07 3 233152 3487 29715836
Intraocular pressure increased 17.47 14.07 9 233146 5111 29714212
Erectile dysfunction 17.39 14.07 77 233078 18025 29701298
Portal vein thrombosis 17.38 14.07 3 233152 3461 29715862
Respiratory tract infection 17.37 14.07 191 232964 15315 29704008
Contusion 17.36 14.07 341 232814 30939 29688384
Sudden death 17.35 14.07 62 233093 15430 29703893
Gastric ulcer 17.28 14.07 60 233095 15061 29704262
Skin atrophy 17.19 14.07 39 233116 1609 29717714
Papillary thyroid cancer 17.17 14.07 23 233132 617 29718706
Gait inability 17.12 14.07 223 232932 18618 29700705
Haematochezia 17.05 14.07 177 232978 34045 29685278
Hemiplegia 17.04 14.07 16 233139 6645 29712678
Abdominal discomfort 17.04 14.07 499 232656 48292 29671031
Humerus fracture 17.02 14.07 49 233106 2344 29716979
Hyperammonaemia 16.98 14.07 11 233144 5509 29713814
Upper-airway cough syndrome 16.92 14.07 53 233102 2657 29716666
Type 1 diabetes mellitus 16.90 14.07 4 233151 3695 29715628
Congestive cardiomyopathy 16.86 14.07 16 233139 6611 29712712
Vertigo 16.85 14.07 105 233050 22530 29696793
Pain 16.73 14.07 1138 232017 171503 29547820
Plasma cell myeloma refractory 16.73 14.07 8 233147 41 29719282
Bradyphrenia 16.71 14.07 5 233150 3952 29715371
Swollen tongue 16.71 14.07 50 233105 13142 29706181
Stevens-Johnson syndrome 16.67 14.07 75 233080 17481 29701842
Colon cancer metastatic 16.62 14.07 39 233116 1646 29717677
Device related infection 16.57 14.07 72 233083 16943 29702380
Respiratory acidosis 16.54 14.07 6 233149 4196 29715127
Electrocardiogram abnormal 16.48 14.07 13 233142 5879 29713444
Loss of consciousness 16.46 14.07 481 232674 78894 29640429
Adenocarcinoma gastric 16.44 14.07 31 233124 1120 29718203
Pyelonephritis 16.44 14.07 11 233144 5415 29713908
Autoimmune hepatitis 16.42 14.07 4 233151 3623 29715700
Disease complication 16.39 14.07 51 233104 2548 29716775
Acute generalised exanthematous pustulosis 16.38 14.07 14 233141 6084 29713239
Urinary incontinence 16.30 14.07 72 233083 16868 29702455
Duodenal ulcer haemorrhage 16.26 14.07 8 233147 4664 29714659
Prostate cancer stage I 16.19 14.07 7 233148 27 29719296
Lyme disease 16.16 14.07 24 233131 710 29718613
Diverticulum intestinal 16.12 14.07 3 233152 3279 29716044
Acute coronary syndrome 16.10 14.07 53 233102 13520 29705803
Gastrointestinal infection 16.09 14.07 65 233090 3700 29715623
Bladder disorder 16.08 14.07 54 233101 2809 29716514
Diverticulitis 16.07 14.07 207 232948 17238 29702085
Squamous cell carcinoma of the hypopharynx 16.07 14.07 6 233149 14 29719309
Chronic kidney disease 16.00 14.07 203 232952 37635 29681688
Gingival discolouration 15.89 14.07 5 233150 5 29719318
Aplastic anaemia 15.87 14.07 12 233143 5544 29713779
Gastric haemorrhage 15.85 14.07 31 233124 9436 29709887
Kidney infection 15.71 14.07 74 233081 4504 29714819
Lymphadenopathy 15.71 14.07 118 233037 24258 29695065
Vital functions abnormal 15.69 14.07 10 233145 97 29719226
Blood glucose increased 15.64 14.07 362 232793 61168 29658155
Ventricular extrasystoles 15.63 14.07 42 233113 11432 29707891
Mental disorder 15.62 14.07 53 233102 13396 29705927
Syncope 15.55 14.07 523 232632 84380 29634943
Pneumothorax 15.48 14.07 69 233086 16124 29703199
Plasma cell myeloma in remission 15.45 14.07 4 233151 0 29719323
Hepatic amyloidosis 15.45 14.07 4 233151 0 29719323
Plasma cells decreased 15.45 14.07 4 233151 0 29719323
Occult blood positive 15.43 14.07 5 233150 3755 29715568
Eye infection 15.43 14.07 53 233102 2789 29716534
Hypothyroidism 15.39 14.07 62 233093 14901 29704422
Feeling jittery 15.31 14.07 65 233090 3783 29715540
Leukoencephalopathy 15.27 14.07 6 233149 3996 29715327
Musculoskeletal chest pain 15.25 14.07 122 233033 8963 29710360
Bundle branch block left 15.17 14.07 11 233144 5193 29714130
Normochromic normocytic anaemia 15.07 14.07 6 233149 3964 29715359
Aplasia pure red cell 15.01 14.07 13 233142 5613 29713710
Blood calcium abnormal 15.00 14.07 18 233137 431 29718892
Immunoglobulins increased 15.00 14.07 12 233143 171 29719152
Anal squamous cell carcinoma 14.96 14.07 9 233146 78 29719245
Salmonellosis 14.96 14.07 23 233132 702 29718621
Hepatitis fulminant 14.89 14.07 6 233149 3935 29715388
Intestinal obstruction 14.87 14.07 221 232934 18991 29700332
Renal amyloidosis 14.83 14.07 8 233147 55 29719268
Central nervous system lesion 14.79 14.07 10 233145 4896 29714427
Psychiatric symptom 14.77 14.07 4 233151 3375 29715948
Cardiotoxicity 14.70 14.07 8 233147 4406 29714917
Dermatitis exfoliative 14.70 14.07 22 233133 7434 29711889
Bone marrow failure 14.66 14.07 319 232836 29466 29689857
Cerebral ischaemia 14.60 14.07 16 233139 6184 29713139
Bilirubin conjugated increased 14.59 14.07 4 233151 3347 29715976
Emotional disorder 14.55 14.07 11 233144 5083 29714240
Transitional cell cancer of the renal pelvis and ureter 14.54 14.07 6 233149 20 29719303
Discomfort 14.44 14.07 60 233095 14296 29705027
Laryngeal oedema 14.34 14.07 4 233151 3310 29716013
Haemorrhagic stroke 14.32 14.07 16 233139 6131 29713192
Gastric infection 14.23 14.07 27 233128 980 29718343
Respiration abnormal 14.11 14.07 49 233106 2593 29716730
Ecchymosis 14.11 14.07 18 233137 6504 29712819

Pharmacologic Action:

SourceCodeDescription
ATC L04AX04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Other immunosuppressants
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D007155 Immunologic Factors
FDA EPC N0000184014 Thalidomide Analog
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:48422 angiostatic agents
CHEBI has role CHEBI:50846 biomodulator

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Follicular lymphoma indication 55150002
Multiple myeloma indication 109989006 DOID:9538
Myelodysplastic syndrome indication 109995007
Mantle cell lymphoma indication 443487006
Marginal zone lymphoma indication 447100004
Deep venous thrombosis contraindication 128053003
Impaired renal function disorder contraindication 197663003
Pulmonary thromboembolism contraindication 233935004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Thromboembolic disorder contraindication 371039008
Primary malignant neoplasm contraindication 372087000
Breastfeeding (mother) contraindication 413712001
Chemotherapy-Induced Hyperuricemia contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.17 acidic
pKa2 3.13 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINULLTION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINULLTION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINULLTION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINULLTION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINULLTION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINULLTION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINULLTION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENULLNCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENULLNCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENULLNCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENULLNCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENULLNCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENULLNCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINULLTION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINULLL ZONE LYMPHOMA (MZL)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein cereblon Cytosolic other MODULATOR EC50 6.53 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Tumor necrosis factor Cytokine IC50 7.89 WOMBAT-PK

External reference:

IDSource
4025089 VUID
N0000175347 NUI
D04687 KEGG_DRUG
4025089 VANDF
C1144149 UMLSCUI
CHEBI:63791 CHEBI
CHEMBL848 ChEMBL_ID
D000077269 MESH_DESCRIPTOR_UI
DB00480 DRUGBANK_ID
7331 IUPHAR_LIGAND_ID
8505 INN_ID
F0P408N6V4 UNII
216326 PUBCHEM_CID
337535 RXNORM
20816 MMSL
73707 MMSL
d05696 MMSL
011171 NDDF
421471009 SNOMEDCT_US
421737001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-402 CAPSULE 2.50 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-405 CAPSULE 5 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-410 CAPSULE 10 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-415 CAPSULE 15 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-420 CAPSULE 20 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-425 CAPSULE 25 mg ORAL NDA 32 sections